List of Small Molecule Pharmaceuticals Companies in Massachusetts - 264

Accent is leading the translation of RNA-modifying protein (RMP) biology into promising new therapies by combining a robust chemical biology platform with rigorous approaches to target identification and validation. Our seasoned team of drug developers is uniquely experienced to interrogate and advance small molecule therapies with far-reaching potential.

Acta has licensed IP from Massachusetts General Hospital which provides the foundation for its initial two clinical development programs. The first program is the result of the screening from the Tanzi Lab utilizing its Alzheimer’s-in-a-dish™ mini-human brain organoid model to identify and validate dozens of combinations that affect Alzheimer’s brain pathology. Acta will further assess these Combination Therapies and will testing the most promising ones in humans in its Alzheimer’s Disease Combination Trial Initiative. The second development program benefits from a robust Gamma-Secretase Modulator (GSM) patent estate including GSM-776890 - one of the most promising amyloid-lowering novel Alzheimer’s drugs which Acta is readying to enter clinical trials.

Discovering novel functions of existing molecules

Adecto is a pre-clinical stage, cancer therapeutics company, developing the first targeted therapy against ADAM8-expressing cancers and a companion diagnostic to identify patients who can benefit from it. ADAM8 is a critical driver of the growth and spread of many aggressive tumors, including those of the breast, stomach, colon, lungs, liver and pancreas, and is associated with poor patient survival. Adecto’s current focus is on breast cancer with a plan to expand to other oncology indications in the future.

At Adiso, we create medicines to treat inflammatory diseases, improving the lives of patients and their families. Current treatment paradigms are far too often either inadequate to halt disease progression or burden the patient with significant safety concerns. To tackle these challenges, we are advancing an innovative pipeline of small molecules and single strain live biotherapeutic products (SS-LBP) both with novel mechanisms of action. ADS024 (SS-LBP) is currently being evaluated in a Phase 1b study for the prevention of recurrent CDI and a Phase 2 study in mild-to-moderate ulcerative colitis (UC). ADS051 is currently enrolling a Ph1b study in moderate-to-severe ulcerative colitis (UC). Adiso is also developing a novel dual inflammasome inhibitor in discovery phase which is being initially explored in respiratory inflammation, with multiple future therapeutic areas to pursue.

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of hematologic malignancies, solid tumors, and rare genetic diseases. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA, an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted cancers; and AG-636 that is in pre-clinical stage for treating hematologic malignancies. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts.

Agrivida is a biotechnology company focused on developing and commercializing a new generation of enzyme solutions to feed livestock more efficiently, reduce negative environmental impacts, and produce more healthful food for an expanding consumer population. Agrivida’s first product, GRAINZYME® Phytase, grows enzymes that are crucial for livestock’s health and well-being directly inside the animals’ corn feed. The enzymes improve feed digestibility, increase mineral availability, and reduce nutritional inhibitors within the animals. The traditional process for enzyme delivery is costly and inefficient. It requires enzyme additives to be administered alongside animal feed, and the process for producing the enzymes is complicated, generates excess waste, and requires tremendous energy. By growing necessary enzymes directly inside the feed, Agrivida eliminates the need for these enzyme additives, ultimately reducing costs to farmers, minimizing feed waste, and improving the environmental footprint of the entire process. Agrivida’s team is led by food and agribusiness industry executives and scientists with expertise in the fields of biochemistry, plant biology, molecular biology, and nutrition.

Boston-based AI Proteins is a biotech company on a mission to re-imagine protein therapeutics with a novel approach for designing entirely new proteins. Using AI-based design and a high-throughput drug discovery platform, AI Proteins creates de novo proteins optimized for specific therapeutic applications. The AI Proteins platform enables the development of inexpensive, durable, highly specific proteins that have the potential for oral delivery. Additionally, the AI Proteins platform can dramatically accelerate the development of lead therapeutic candidates ready for IND enabling studies.

Ajax Therapeutics is a biotechnology company developing precision therapies for blood cancers called hematologic malignancies. The company has a unique partnership with Schrödinger, Inc. to develop novel small molecules targeting cytokine signaling pathways for hematologic malignancies.

Akashi Therapeutics is a clinical stage biotechnology company developing a portfolio of products for Duchenne muscular dystrophy and other rare diseases. The lead clinical asset is HT-100, and drug candidate with potent anti-inflammatory and anti-fibrotic properties that also promotes healthy muscle regeneration. The company's second clinical candidate is DT-200, a Selective Androgen Receptor Modulator (SARM), targeted to build muscle mass and strength.

Since our founding in 2007, we’ve put tenacity and innovation to work to develop novel therapeutics that have the potential to set new standards of care for people living with kidney disease. We have emerged as a leader with deep roots in the renal community. Today, we are a fully integrated biopharmaceutical company with both an experienced nephrology-focused commercial team and a robust development organization.

Aktis Oncology is a biotechnology company dedicated to realizing the curative power of alpha radiopharmaceuticals for the mainstream of cancer care.

Alcresta Therapeutics is dedicated to developing and commercializing novel, enzyme-based products designed to address challenges faced by people living with gastrointestinal disorders and rare diseases. The company uses its proprietary technology platform to support a broad pipeline of products, with an initial focus on pancreatic insufficiency or fat malabsorption, which results in malabsorption common in cystic fibrosis, digestive cancers, preterm birth, and other serious diseases. The company’s lead product, RELiZORB®, is designed to reliably and efficiently deliver the optimal nutritional and caloric benefit from existing enteral feeding formulas by improving the breakdown and absorption of fats, in particular long-chain polyunsaturated fatty acids like omega-3 (including DHA, EPA). RELiZORB is indicated for use in pediatric patients (ages 5 years and above) and adult patients to hydrolyze fats in enteral formula. The company’s platform is supported by our extensive experience in pharmaceutical, medical device and nutritional product development. Based in Massachusetts, the company is backed by top-tier venture investors Athyrium Capital Management, Bessemer Venture Partners, Frazier Healthcare, and Third Rock Ventures.

Aldeyra Therapeutics discovers and develops innovative therapies designed to treat immune-mediated diseases. Our approach is to develop therapies that modulate immunological systems, instead of inhibiting or activating single targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 proof-of-concept clinical trials in psoriasis, asthma, and COVID-19. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma.

Our mission is to transform the lives of people living with rare diseases and devastating conditions through the development and delivery of innovative medicines, as well as through supportive technologies and healthcare services. By continuing to deepen our understanding of rare disease, which began with our pioneering work in complement biology, we are able to innovate and evolve into new areas where there is great unmet need and opportunity to help patients and families fully live their best lives. Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work. We invest in and value people who believe in the importance of our purpose and understand what it takes to deliver on it. Alexion has over 3,000 talented colleagues dedicated to serving people living with rare diseases in more than 50 countries around the world. Our global headquarters are based in Boston, Massachusetts and our EMEA headquarters are in Zürich, Switzerland. We also have a Research Center of Excellence in New Haven, Connecticut, global supply chain and operations headquarters in Ireland, as well as local and regional operations in countries around the world. At Alexion, our passion drives us to continuously innovate and create meaningful value in all we do. In doing so, we change lives for the better – ours, people living with rare diseases, and the communities we serve. Every day.

Alnylam is the world's leading RNAi therapeutics company and the first and only company to bring RNAi-based medicines to market. We are developing RNAi (RNA interference) as an innovative, entirely new class of medicines to treat rare genetic, cardio metabolic, acute hepatic infectious and central nervous system (CNS) and ocular diseases. Alnylam was founded in 2002 based on a Nobel Prize-winning breakthrough in biology – the discovery of RNAi, and a bold vision that this discovery could be used to silence disease-causing genes upstream of today’s medicines. We are relentless in our pursuit of new treatments because we believe that RNAi therapeutics can be used to treat many diseases for which treatment options do not exist or are inadequate. Alnylam is turning scientific possibility into reality - in 2018, the FDA and EMA approved of our first product, ONPATTRO (patisiran) which is also the first-ever approved RNAi therapeutic. We now have three additional medicines on the market: GIVLAARI (givosiran), OXLUMO (lumasiran) and LEQVIO (inclisiran) in partnership with Novartis). Our robust pipeline of investigational medicines includes multiple programs in late-stage and early-stage clinical development. We are a global and diverse company of more than 1,700 people. We pride ourself on fostering a fun, inclusive and dynamic work environment where employees can recognize their fullest potential. That's why we've been named a Science Magazine Top Employer 3 years in a row ('19-'21), a Boston Globe Top Place to Work 7x in a row ('15-'21) and one of Fast Company's Best Workplaces for Innovators for 2021.

Alopexx Enterprises works with scientists and entrepreneurs to build successful new companies. We invest in novel health care technologies at all stages of development and can serve as a lead investor or collaborate with a group of investors to advance important science. We also have the capabilities to provide management and development expertise where needed. To date, our initial investments have ranged from $1-20M. The Alopexx team consists of experts who have deep industry knowledge and technical expertise in all areas of drug development including, pharmacology, CMC, toxicology, medical and clinical operations, quality and regulatory affairs. We form collaborations with academic institutions, biotech and pharmaceutical companies to advance our portfolio companies to deliver breakthrough therapies to patients in need. Our business model is to invest and develop to an important inflection point and then partner the asset for further development and/or commercialization. Portfolio companies include: -Alopexx Pharmaceuticals -Alopexx Oncology -Alopexx Vaccine -Valerion Therapeutics -Janus Biotherapeutics -Cognoptix

Alseres Pharmaceuticals, Inc. (ALSE) is focused on the development of diagnostic and therapeutic products for disorders in the central nervous system (CNS).

Launched in February 2024, Alys Pharmaceuticals is an innovation leader in immuno-dermatology, co-founded by Medixci and world-leading dermatology and scientific experts. Originating from the aggregation of six asset-centric Medixci compannies, Alys boasts a robust pipeline of innovative programs and platforms targeting multiple dermatological indications. With a vision to transform the treatment paradigm for several dermatology indications of significant prevalence and major unmet medical need, Alys aspires to redefine the landscape of dermatological treatments.

Alyssum Therapeutics, a biotechnology company which is developing next-generation immunotherapies to modulate B cells

Alzheon, Inc. is committed to developing innovative medicines by directly addressing the underlying pathology of devastating neurodegenerative disorders. Our lead Alzheimer’s clinical candidate, ALZ-801, is an oral small molecule prodrug of tramiprosate that fully blocks formation of neurotoxic soluble amyloid oligomers in the brain. ALZ-801 is an easy-to-take tablet that builds on the safety and efficacy profile of its active compound tramiprosate, which has been evaluated in clinical trials involving over 2,000 Alzheimer’s patients. Our clinical expertise and technology platform are focused on developing drug candidates using a precision medicine approach based on individual genetic and biological information to advance therapies with the greatest impact for patients. www.alzheon.com

AmberGen® is a biotechnology company and producer of Miralys™ spatial biology imaging solutions. Miralys™, also known as MALDI HiPLEX-IHC, is a new breakthrough method for targeted intact protein imaging that has unique multimodal imaging capabilities. First introduced in 2022, it has gained significant traction, including 8 of the top 10 pharma companies, as well as many of the world's premier research institutions. It is currently being used to study tissues for a wide range of diseases including cancers, Alzheimer's and Parkinson's diseases; and even COVID. Benefits include: - Drug/target co-localization on the same sample, same instrument - The ability to produce images that co-register small molecule lipids and metabolites as well as the intact targeted proteins. - The product's combination of fast, targeted, protein imaging (scan time as short as 45 min and 1cm2), ultra-high plex (10 to 100+), wide viewing area (up to 25 x 75 mm), and multi-modal capability make it an ideal technology for doing initial scans to identify regions of interest for later deep-dive analysis. - Miralys™ requires no dedicated instrument, and minimal investment to start using. It is used on MALDI Mass Spec Imaging instruments that your institution most likely already owns, such as the industry-leading instruments from our partner, Bruker Corporation.

Ampersand Biomedicines enables a new way of designing programmable medicines that work precisely where needed in the body and nowhere else. The company’s state-of-the-art computationally powered Address, Navigate, Design (AND)™ Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of localizers and actuators. The result is increasingly sophisticated AND-Body™ therapeutics that are engineered across the physical constraints of molecules and the biological characteristics of the targets to effectively target the site of disease without affecting healthy tissue or cells. Ampersand Biomedicines was founded in 2020 at Flagship Labs, a unit of Flagship Pioneering.

Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company’s product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Anagram is a clinical stage company leveraging proprietary enzyme technologies and expertise in gastrointestinal diseases to solve complex problems and advance a pipeline of products that can make a life-changing impact for people and their families living with cystic fibrosis and other rare diseases. Malabsorption syndromes and nutrient metabolism disorders prevent the body from properly processing or absorbing certain fats, sugars, proteins, vitamins or other key nutrients. ANG003, Anagram’s lead product is intended for the treatment of malabsorption and exocrine pancreatic insufficiency and is a new class of broad-spectrum digestive enzyme replacement therapy.

Ankyra is developing a novel approach for cancer treatment called Anchored Immunotherapy, promoting prolonged immune activation locally while limiting systemic toxicity.

Anodyne is a venture-backed, clinical-stage biotech company focused on simplifying chronic care for all stakeholders. We specialize in the transdermal delivery of multi-milligram doses and complex formulations, enabling easier access to both existing therapies and emerging large molecule treatments. The HeroPatch, our proprietary technology represents a breakthrough in drug delivery. By transdermally delivering large molecules, it enables tunable pharmacokinetic profiles, new formulations using APIs in dry form, room temperature stability, and combination therapies of next-generation therapeutics. Our product pipeline is dedicated to addressing the unmet needs of chronic diseases, with an initial focus on obesity. We are committed to delivering innovative solutions that significantly impact patients' lives. Anodyne is actively expanding its pipeline through both internal clinical development and strategic external partnerships, maximizing the commercial potential and clinical impact of our advanced drug delivery platform.

Ansella Therapeutics is a specialty pharmaceutical company that leverages biomimetic sciences to develop novel therapeutics that improve healthcare outcomes.

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.

Aprea Therapeutics Inc., (NASDAQ: APRE) is a biopharmaceutical company headquartered in Boston, Massachusetts with research facilities in Stockholm, Sweden, focused on developing and commercializing novel cancer therapeutics to reactivate the mutant tumor suppressor protein p53, the most commonly mutated gene in cancer

Ardelyx was founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs. Ardelyx has two commercial products approved in the United States, IBSRELA® (tenapanor) and XPHOZAH® (tenapanor). Ardelyx has agreements for the development and commercialization of tenapanor outside of the U.S. Kyowa Kirin commercializes PHOZEVEL® (tenapanor) for hyperphosphatemia in Japan. A New Drug Application for tenapanor for hyperphosphatemia has been submitted in China with Fosun Pharma. Knight Therapeutics commercializes IBSRELA in Canada. Community Guidelines: https://rb.gy/07ltg3

Arkuda Therapeutics is a biotechnology company leveraging new insights into progranulin and lysosomal biology to develop medicines to change the trajectory of neurodegenerative disease.

Arrakis has a simple but powerful vision: To extend small-molecule medicines into new realms of biology, unlocking that biology for medicine. Our approach builds on the existing sophisticated drug discovery toolkit developed for protein targets, which we are adapting and refocusing on discovering small-molecule compounds that act directly on RNA.

Artax Biopharma is a development-stage biopharmaceutical company dedicated to the development of new therapies for autoimmune and inflammatory diseases. Artax Biopharma is developing the next generation of drugs targeting the interaction between TCR and Nck, which is responsible for T-cell activation. Specific control over T-cells through TCR, provides the compounds with the potential to become first-in-class immunomodulators for the treatment of a wide range of autoimmune and inflammatory diseases.

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company focused on developing a new class of alpha radioligand therapies (ART). Our unique patient-centric approach is underpinned by a deep understanding of cancer biology and the infrastructure needed to effectively design, manufacture, and distribute our therapies.

Atacama Therapeutics is a dermatology company focused on advancing treatment for skin and musculoskeletal diseases. The company's pipeline includes AT-5214, a small molecule drug for the treatment of malignant hypertension.

We are a biotechnology company pioneering new treatment options for neurodegenerative diseases by utilizing our proprietary RNA interference platform. We were founded by Anastasia Khvorova, Ph.D., Craig Mello, Ph.D., and Neil Aronin, M.D., of the RNA Therapeutics Institute at the University of Massachusetts Medical School, with a Series A funding exclusively by F-Prime Capital. We are headquartered in Boston, Mass

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for severe viral diseases. The company's lead product candidate is AT-527, a novel antiviral agent for the treatment of patients infected with severe acute respiratory syndrome coronavirus 2 and is under phase 3 clinical trial. It also develops AT-787 which is under phase 2 clinical for the treatment of hepatitis C virus; AT-752 which is under phase 2 clinical trial for the treatment of dengue; and AT-889, AT-934, and other product candidates for the treatment of respiratory syncytial virus are under phase 2 clinical trials. The company was incorporated in 2012 and is based in Boston, Massachusetts.

Auron Therapeutics is a privately held patient-centered, platform-powered, product-driven oncology company. We are the leaders in identifying and targeting cell state to treat a range of solid tumors and hematological malignancies.

AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering and developing targeted therapies designed to provide substantial impact in patients’ lives with clear unmet medical needs. AVEO’s proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. For more information, please visit the company’s website at www.aveooncology.com.

Axial Therapeutics™ is a clinical-stage biopharmaceutical company focused on the discovery and development of gut-restricted, small molecule therapeutics for central nervous system (CNS) disorders. The company is leveraging its expertise in the gut-brain axis and its unique drug development platform to advance novel therapies that have the potential to transform the treatment paradigm in neurodegenerative diseases.

Axonis Therapeutics is a Boston-based, neuro-focused biotechnology company developing first- and best-in-class medicines targeting KCC2, the critical mediator of inhibitory neurotransmission within the brain, by translating breakthrough discoveries spun out from Boston Children’s Hospital, Harvard and Laval University. The company has built a proprietary KCC2 discovery engine, based on several years of world-leading know-how, to become the leaders in this potentially blockbuster drug space. Axonis’ lead development candidate, AXN-027 is a first-in-class oral small molecule designed to potentiate the function of KCC2, a major CNS chloride transporter essential for inhibitory neurotransmission, for the treatment of epilepsy and pain. Axonis recently closed a $115 Million Series A financing co-led by Cormorant Asset Management and venBio Partners with significant investments from Sofinnova Investments, MRL Ventures Fund (Merck & Co., Rahway, NJ), Perceptive Advisors, Solasta Ventures and Lumira Ventures. Axonis is grateful for grant awards received from NIH, DoD, Wings for Life, MLSC, Praxis SCI, CURE Epilepsy, ISSNL and SynGAP Foundation. The company is headquartered in Boston, MA. For more information, visit www.axonis.us.

Azurity Pharmaceuticals is a privately held, specialty pharmaceutical company that focuses on innovative products that meet the needs of patients with underserved conditions. As an industry leader in providing unique, accessible, and high-quality medications, Azurity leverages its integrated capabilities and vast partner network to continually expand its broad commercial product portfolio and robust late-stage pipeline. The company’s patient-centric products span the cardiovascular, neurology, endocrinology, gastro-intestinal, institutional, and orphan markets, and have benefited millions of patients.

Bay BioSciences provides high quality human biomaterials, fresh frozen human tissues, FFPE Tissue Blocks, bio fluids like whole blood from diseased and normal subjects, serum, plasma and other blood products. Bay BioSciences specializes in characterized and documented human bio-specimens for research and development projects and is a leading global biobank offering vital products and services facilitating breakthroughs in translational medicine, genetics, drug discovery, biomarker research, companion and molecular diagnostics.

BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin’s lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company’s clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. On November 14, 2024, the company announced its intent to change the Company’s name to BeOne Medicines Ltd., confirming its commitment to develop innovative medicines to eliminate cancer by partnering with the global community to serve as many patients as possible.

We provide you with the best experts in the biopharma industry. Through our flexible, consultative approach, we'll align you with professionals with the expertise you need when you need them the most. From early clinical and device development to the post-market phase, we help you bridge your expertise gaps.

Through cutting-edge science and medicine, Biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. Founded in 1978, Biogen is a pioneer in biotechnology and today the Company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis. Biogen also manufactures and commercializes biosimilars of advanced biologics. With approximately 7000 people worldwide, we are truly a global organization, headquartered in Cambridge, Massachusetts, which is also home to our research operations. Our international headquarters are based in Zug, Switzerland and we have world-class manufacturing facilities in North Carolina and Denmark. We offer therapies globally through direct affiliate presence in 30 countries and a network of distribution partners in over 50 additional countries.

Developing new drugs under FDA regulation for hypoxia brain and heart ischemia and viral infection like coronavirus and influenza.

Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry.

Blueprint Medicines Corporation, a precision therapy company, develops drugs of small molecule kinase inhibitors that target genomic drivers in genomically defined cancers, rare diseases, and cancer immunotherapy. The company is developing avapritinib for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM and other mast cell disorders; and fisogatinib, an orally available and potent inhibitor, which is in Phase I clinical trials for the treatment of advanced hepatocellular carcinoma. It is also developing pralsetinib, an orally available and potent inhibitor that targets RET, a receptor tyrosine kinase for the treatment of RET-altered non-small cell lung cancer, medullary thyroid carcinoma, and other solid tumors. In addition, the company is developing BLU-782, an oral and investigational activin-like kinase 2 inhibitor, which is in Phase I clinical trials for the treatment of fibrodysplasia ossificans progressive. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; CStone Pharmaceuticals; Genentech, Inc.; and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was founded in 2008 and is headquartered in Cambridge, Massachusetts.

Bold and nimble, Boston Oncology is an innovative biogenerics company redefining excellence in the licensing and local development, manufacturing and distribution of US- quality medicines – across therapeutic areas. From our nerve center in Riyadh, we leverage the expertise, daring creativity, and unwavering determination of our international leadership team to provide customers with end-to-end, efficient, single-point-of-contact access to our diverse portfolio of world-class biogenerics. We do this because lives depend on it.

Transforming the right molecules into the best medicines™ Boston Pharmaceuticals acquires and transforms innovative molecules into differentiated medicines that improve patients’ lives. We have rapidly built a portfolio of high-value candidates across multiple therapeutic areas and are actively seeking additional programs for our diverse pipeline.

BPGbio is a clinical-stage biopharma reimagining how patient biology can be modeled using unbiased AI algorithms, to accelerate and de-risk the process of drug discovery for humanity. Our Interrogative Biology® platform has produced and guided development of more than a dozen therapeutics and diagnostics candidates in the areas of oncology, neurology and rare diseases, including several in advanced clinical stages. As BPGbio continues to expand our biobank, and the network insights that are derived from it, we anticipate more promising discoveries made with improved time and cost efficiency.

Sebela Pharmaceuticals is a U.S. pharmaceutical company with a market-leading position in Gastroenterology and a focus on innovation in Women's Health. Our Vision is to build the leading Gastroenterology company in the U.S., with a complementary focus on innovation in Women's Health, premised on our expertise in pharmaceutical development and commercialization. We value dedication, energy, and enthusiasm, and we focus on innovation and results while striving to achieve our corporate mission and vision. Sebela Pharmaceuticals is committed to cultivating an inclusive environment where all employees are treated with respect. We accomplish this by fostering a culture of diversity, equity and inclusion, which is essential to innovation and continuous improvement. Sebela operates from three locations with offices in Roswell, Georgia, Braintree, MA and headquarters in Dublin, Ireland.

BYOMass is a preclinical pharmaceutical company developing novel biologic and small molecule drugs to modulate specific members of the TGF-β superfamily, for the treatment of orphan and common diseases of high unmet medical need. Selectively targeting specific members and pathways within the TGF-β superfamily has the potential to be a meaningful class of therapeutics within oncology, inflammatory/immune, fibrotic, and metabolic diseases.

C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes.

Cadent Therapeutics is rapidly advancing apipelineof novel allosteric modulators of ion channels – taking a well-established pharmaceutical approach and stepping out into new territory.SK channels and NMDA receptors are ion channels that are critical formodulating the strength, timing, and integration ofcommunication betweenand within neurons and neuronal networksin the central nervous system.

Calosyn has developed intra-articular therapeutic drugs for osteoarthritis of the knee based on proprietary combinations of ion channel modulators (ICM’s) currently in clinical use.

At Candel Therapeutics, we are developing immunotherapies that induce immunogenic cell death in cancer cells at the site of injection, unmasking tumor neo-antigens within an activated microenvironment. This process leads to a systemic, durable immune response against the tumor, with the potential to change disease outcomes across a variety of indications. Candel’s products are designed to improve survival while maintaining quality of life – from early- to late-stage disease.

Cardurion Pharmaceuticals is a next generation cardiovascular company focused on the discovery and development of novel therapeutics for the treatment of heart failure and other cardiovascular diseases. Led by an experienced team of CV experts and industry veterans, we are developing groundbreaking clinical programs in PDE9 and CaMKII inhibition. We take a strategic portfolio approach driven by in-house drug discovery and our office of strategy and have concluded foundational partnerships with key strategics and investors, including an up to $300 million dollar investment from Bain Capital to support current programs and pipeline growth. Cardurion Pharmaceuticals has facilities in Burlington, Massachusetts and Shonan, Japan. For more information, please visit the company’s website at http://www.cardurion.com.

Headquartered in Beverly, Massachusetts, Cellceutix is a publicly traded company under the symbol “CTIX”. Cellceutix is a clinical stage biopharmaceutical company developing innovative therapies in oncology, dermatology and antibiotic applications. Please visit Cellceutix's web site at www.cellceutix.com.

Cerevance is a revolutionary pharmaceutical company using the proprietary NETSseq platform to develop novel symptomatic and therapeutic treatments for central nervous system (CNS) disorders.

Cerevel Therapeutics is working relentlessly to find paths through complexity in an effort to bring real progress and new treatment options to people living with a broad range of neuroscience diseases. On August 1, 2024, AbbVie has acquired all outstanding Cerevel common stock for $45.00 per share. It is expected that Cerevel's common stock will cease to trade on the NASDAQ stock exchange prior to market open on August 1, 2024. This acquisition is expected to be accretive to adjusted diluted earnings per share (EPS) beginning in 2030.

CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry. In August, 2023 EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIP’s development pipeline, but changing their name to CervoMed (CRVO). For more information about the company and updates, please visit www.cervomed.com/ or follow us on Twitter at @Cervo_Med.

At Charles River, we are passionate about our role in improving the quality of people’s lives. Our mission, our excellent science and our strong sense of purpose guides us in all that we do, and we approach each day with the knowledge that our work helps to improve the health and well-being of many across the globe.

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, in a Phase 1/2 clinical trial for the treatment of patients with EGFR mutation-positive non-small cell lung cancer (“NSCLC”). In addition, Checkpoint is currently evaluating its lead antibody product candidate, CK-301, an anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in a Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers. Checkpoint plans to develop CK-301 as a treatment for patients with NSCLC and other solid tumors. Checkpoint is a majority-controlled subsidiary of Fortress Biotech, Inc., and is headquartered in New York City.

Founded by pioneering executives and scientists in RNAi, City Therapeutics is advancing next-generation engineering of small interfering RNAs (siRNAs) – the “trigger” molecules that mediate RNAi – to improve and expand the reach of RNAi-based medicines. City’s mission is to build the leading next-generation RNAi therapeutics company, unlocking RNAi’s transformative potential to help patients with a wide range of diseases.

Cocoon Biotech is a biotechnology company that specializes in developing a drug-delivery platform using fibroin protein derived from silkworm cocoons.

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. Cogent Biosciences, Inc. has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of CGT9486 and CGT0206 inhibitors. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.

Collegium Pharmaceutical is a specialty pharmaceutical company committed to being the leader in responsible pain management. For nearly two decades, Collegium has been focused on developing and commercializing new medicines for pain management that reflect our Core Values and our commitment to people suffering from pain, providers and our communities. The result of those efforts is a portfolio of meaningfully differentiated medications to treat moderate to severe pain.

Conagen is an accomplished biotechnology company located in the greater Boston biotech corridor. We innovate and develop synthetic biology solutions for supporting global partners across a spectrum of current and developing markets. From our proprietary strain development to fermentation and process scale-up, Conagen impacts partners’ abilities to sell and market products in the food, nutrition, flavor and fragrance, pharmaceutical, and renewable materials industries. Our bio-manufacturing capabilities, coupled with extensive platforms of enzymes and microorganisms, gives us the edge in commercial biotechnology. Nature is our inspiration for designing metabolic pathways, improving production organisms, and optimizing production processes. Our discovery and development methods foster sustainability and improve efficiency—from lab to world scale. Plant biology ignited the spark for the creation of Conagen. Today, our bioengineering teams are experts in enzymatic bioconversion and fermentation technology. Nature is our guide for innovating ways to produce natural products and materials. This approach gets us to market faster with better products made competitively and sustainably. Simply, our distinction is creating molecules that are identical to what nature produces. Many of the innovative natural products we make at Conagen are truly proprietary. They are the only ones on the market that are made by natural fermentation which means they are produced biologically and sustainably unlike most chemically synthesized products. As a vertically integrated biotech company, we engage in research and development as well as world-scale production. The advantage at Conagen is our ability to direct the manufacturing of our products. We can rapidly scale our strains to produce what our partners need while maintaining the highest level of quality control throughout the entire process. Scaling up from micrograms to metric tons is our expertise.

We are pioneering a new class of drugs that activate the immune system to recognize cancer cells as foreign invaders.

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of rationally designed, endocannabinoid system-targeting drug candidates. The Company’s lead product candidate, lenabasum, is a novel, oral, selective cannabinoid receptor type 2 (CB2) agonist rationally designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis and systemic lupus erythematosus. Corbus is also developing a pipeline of drug candidates targeting the endocannabinoid system. The pipeline includes CRB-4001, a 2nd generation, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to be peripherally restricted. Potential indications for CRB-4001 include nonalcoholic steatohepatitis (NASH), among others.

Courage Therapeutics is a pre-clinical biotech company focused on feeding behavior. The company has established a platform for creating receptor subtype

Our Mission is to treat diseases with first-and best-in-class covalent therapeutics for the most significant drug targets by leveraging our cutting-edge capabilities and expertise in chemistry, quantitative proteomics, translational sciences, and deep learning.

Cullinan Therapeutics is a biopharmaceutical company dedicated to creating new standards of care for patients. They have strategically built a diversified portfolio of clinical-stage assets across oncology and immuno-oncology, as well as autoimmune diseases. The company is focused on developing innovative therapies to address unmet medical needs and improve patient outcomes.

Cure Rare Disease™ is developing advanced therapeutics for those who have been diagnosed with rare, genetic diseases that have no treatment or cures. Through partnerships and collaboration, our world-renowned researchers build life-saving therapeutics that are intended to stop or reverse the progression of disease.

Curis is a publicly-traded biotechnology company (NASDAQ: CRIS) focused on the development of first-in-class and innovative therapeutics or the treatment of cancer. The Company currently has three drug candidates in development: - Emavusertib (CA-4948), an orally-available, small molecule inhibitor of the IRAK4 kinase being investigated in a Phase 1 clinical trial in patients with non-Hodgkin's lymphoma and in a separate Phase 1 trial for acute myeloid leukemia and myelodysplastic syndromes. - CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation, or VISTA signaling pathway, being investigated in a Phase 1a/1b trial in patients with solid tumors. - Fimepinostat, an orally available, small molecule inhibitor of HDAC and PI3K enzymes, which is currently being evaluated for future studies. Curis is engaged in a collaboration with Aurigene for discovery and development of drug candidates in the area of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule dual antagonists of PD1 and VISTA, including PDL1/VISTA antagonist CA-170, and oral small molecule dual antagonists of PD1 and TIM3, including PDL1/TIM3 antagonist CA-327, as well as to molecules designed to inhibit the IRAK4 kinase, including CA-4948. The Company's collaborators, F. Hoffmann-La Roche Ltd, or Roche, and Genentech Inc., or Genentech, a member of the Roche Group, are commercializing Erivedge®(vismodegib) for the treatment of patients with advanced basal cell carcinoma, or BCC. We are seeking dedicated, driven, humble, hands-on professionals, from diverse backgrounds, who are passionate about making a difference in the lives of patients and families touched by cancer, and who want to have some fun while doing it. For more information, visit Curis's website at www.curis.com.

Cyclerion Therapeutics is a clinical-stage biopharmaceutical company applying neurological insights to discovery, develop, and commercialize innovative medicines for people with serious diseases of the central nervous system (CNS). Lead programs include IW-6463, a pioneering CNS-penetrant sGC stimulator in clinical development for Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS) and Alzheimer's Disease with Vascular pathology (ADv).

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing immunokinase inhibitors comprising vimseltinib (DCC-3014) that is in Phase 1b/2 clinical trial for the treatment of tenosynovial giant cell tumors; and Rebastinib, which is in Phase 1b/2 clinical trial to treat metastatic solid tumors, as well as to investigate in combination with chemotherapy for the treatment of multiple solid tumors. In addition, it is developing DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. The company serves in the United States and Europe. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Engineering broad acting antivirals that target the viruses of today and pre-emptively protect against the viruses of tomorrow.

DeepCure is transforming the field of small-molecule drug discovery, by delivering better drugs in a faster and cheaper way. The company was founded to accelerate breakthrough science, developed by world-leading AI engineers, data scientists and biologists. DeepCure does not use AI to simply generate a profile of the target candidate profile (TCP), but instead re-engineers drug discovery to deliver transformative results.

Delix Therapeutics is applying modern tools of pharmaceutical development to some of nature's most ancient therapies, psychedelics. Through its discovery platform, Delix has identified a new class of non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. Delix is rapidly advancing these psychoplastogen compounds through preclinical and clinical development, with the goal of one day alleviating mental suffering through its FDA-approved, take-home medicines.

Delphia Therapeutics is a biotechnology company pioneering activation lethality, a new area of cancer therapeutics that target cancer's surprising vulnerability to oncogene overactivation. Delphia’s activation lethality platform offers the potential for first-in-class targeted cancer medicines that are effective on their own while also combating the emergence of drug resistance to classic targeted therapies.

Dermata Therapeutics, Inc. (Nasdaq: DRMA) is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. The Company's lead product candidate, DMT310, is the first product candidate being developed from its Spongilla technology platform. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 is currently under clinical development for the treatment of acne, psoriasis, and rosacea. Our second product candidate, DMT410, uses our Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of multiple aesthetic skin conditions.

Dewpoint is the first company to apply an emerging understanding of biomolecular condensates to drug discovery. Dewpoint develops drugs for the vast range of conditions that are regulated by condensates or arise from the dysfunction of condensates. Dewpoint currently has multiple programs across an ambitious pipeline spanning oncology, neurodegeneration, cardiopulmonary, and virology indications, and collaborations with leading global academic and pharmaceutical partners, including Bayer, Novo Nordisk, Evotec and Chemify. Dewpoint scientists work in Boston, Dresden and Frankfurt to translate condensate biology into breakthrough treatments for diseases previously considered untreatable. 

Disc Medicine is a biopharmaceutical company dedicated to transforming the lives of patients with hematologic disorders. We are building a unique portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology.

Double Rainbow is leveraging the critical role of glycans in human biology to bioengineer anew class of glyco-drug conjugates (GDC) and deliver the next generation of precision medicines.

We formed Edgewood Oncology because of the synergistic mechanism of action and promising safety and anti-tumor data that was observed with BTX-A51 in Phase 1 in AML and solid tumor patients. We look forward to further developing this compound using a precision medicine approach in patient populations who lack effective treatment options. — David N. Cook, Ph.D., Chief Executive Officer

Elektrofi is a biopharmaceutical formulation technology company that is revolutionizing the delivery of biologic therapies by giving patients the ability to control how they want to receive and benefit from life-changing medicines. Our breakthrough hyper concentration microparticle technology platform, Hypercon™, resolves the limitations associated with intravenously delivered biologic therapies by enabling convenient at-home subcutaneous self-administration. With a focus on monoclonal antibodies, therapeutic proteins, and other large molecule drugs, we create, develop, and commercialize subcutaneous biologic therapies in collaboration with strategic partners. We believe a patient-centered healthcare approach can lead to a healthier world. We are headquartered in Boston and innovate globally. Formulating the Future of Biologics™. www.Elektrofi.com

Elion Therapeutics is a cutting-edge biotechnology company dedicated to transforming the treatment of life-threatening fungal infections using a novel approach that’s rooted in structural chemistry. Elion was founded with the belief that mechanistic insights enable targeted optimizations of natural products. Today, Elion is advancing the first polyene antifungal rationally designed to mitigate toxicities and increase safety.

Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel RNA-modulating drug candidates that are designed to treat rare and ultra-rare premature stop codon diseases. Premature stop codons are point mutations that disrupt protein synthesis from messenger RNA. As a consequence, patients with premature stop codon diseases have reduced or eliminated protein production from the mutation bearing allele accounting for some of the most severe phenotypes in these genetic diseases. These premature stop codons have been identified in over 1,800 rare and ultra-rare diseases. Read-through therapeutic development is focused on extending mRNA half-life and increasing protein synthesis by enabling the cytoplasmic ribosome to read through premature stop codons to produce full-length proteins. Eloxx’s lead product candidate, ELX-02, is a small molecule drug candidate designed to restore production of full-length functional proteins. ELX-02 is in the early stages of clinical development focusing on cystic fibrosis and cystinosis. ELX-02 is an investigational drug that has not been approved by any global regulatory body. Eloxx is headquartered in Waltham, MA, with R&D operations in Rehovot, Israel.

Enanta Pharmaceuticals is using its robust chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for viral infections and liver diseases. Enanta’s research and development efforts are focused on the following disease targets: respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), hepatitis B virus (HBV), human metapneumovirus (hMPV) and SARS-CoV-2.

Endolytix Technology, Inc is developing a new therapeutic approach that addresses antibiotic resistance in nontuberculous mycobacterial infections (NTMs)

Entact Bio is a preclinical stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Launched by a founding team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small-molecule drug development, Entact has designed its proprietary Encompass™ platform to create enhancement-targeting chimeric (ENTAC™) medicines. ENTACs harness the ability of DUBs to regulate proteins. By leveraging this natural cellular mechanism to enhance protein function, Entact is expanding the universe of treatable diseases.

Entrinsic Bioscience is a biotechnology company that specializes in developing functional ingredients and Active Pharmaceutical Ingredients (APIs) through a proprietary platform centered on amino acid combinations. The company utilizes a biomapping and electrophysiology platform to identify and patent specific amino acid combinations that influence protein regulation and cell signaling. This technology has its origins in research conducted with NASA, aimed at addressing gastrointestinal damage from ionizing radiation during deep space missions. The company offers a range of applications, including products for pulmonary health, digestive health, immune regulation, metabolism, hydration, and skin health. One of its notable products is enterade IBS-D, a non-prescription medical food designed to manage symptoms of IBS-D. Entrinsic collaborates with healthcare providers, academic institutions, and global partners to commercialize its formulations, focusing on science-backed, plant-based solutions that enhance health outcomes.

Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in clinical development trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also engages in developing EDP1867, an inactivated investigational oral biologic for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor that is in Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.

Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company’s lead candidate is CP101, an orally administered microbiome capsule that has completed Phase II clinical trial for the treatment of patients with recurrent Clostridioides difficile infection, as well as for the treatment of chronic hepatitis B virus. It is also developing FIN-211, an orally administered enriched consortia product candidate for use in the treatment of autism spectrum disorder; and FIN-524 and FIN-525, which are orally administered targeted consortia product candidates for the treatment of ulcerative colitis and crohn’s disease. The company has collaboration and license agreements with Millennium Pharmaceuticals, Inc.; Skysong Innovations LLC; and University of Minnesota. Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Somerville, Massachusetts.

Flare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of its scientific founders, Flare’s team has uncovered ‘switch sites,’ druggable regions that are key targets fortranscription factor regulation to address mutations that cause disease. Its drug discovery to target switch sites has rapidly advanced, resulting in an emerging pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology with future potential in neurology, rare genetic disorders, immunology, and inflammation.

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM for the treatment of metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia; and FHD-609, a small molecule protein degrader of BRD9 to treat patients with synovial sarcoma. The company is also developing an enzymatic inhibitor and a protein degrader as selective modulators of BRM; and ARID1B selective modulators for the treatment of ovarian, endometrial, colorectal, bladder, and gastric cancers. Foghorn Therapeutics Inc. has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel therapeutics based on disruptors of a specified transcription factor target. The company was founded in 2015 and is headquartered in Cambridge, Massachusetts.

ForwardVue Pharma is an emerging biopharmaceutical company developing a small synthetic compound caroboxyamidotriazole, that acts via the novel mechanism of ORAI-1 inhibition and can be formulated to deliver potent anti-angiogenic effects for 6-12 months. Carboxyamidotriazole has been administered to over 900 patients systemically to treat advanced cancer thereby allowing more rapid progress to Phase 2 once IND enabling ocular toxicity is completed. ForwardVue Pharma has secured initial seed round funding in order to advance pre-clinical development of potent long acting anti-angiogenic molecules directed against diabetic eye disease and neovascular age related macular degeneration.

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression.

Galecto is a clinical stage biotechnology company committed to the development of novel small molecule therapeutics directed at biological targets which are at the heart of fibrosis, inflammation, and cancer. Galecto was founded by leading fibrosis-focused scientists and biotech executives and is built on more than 10 years of research into galectin and fibrosis modulators. Our team has developed a deep understanding of the galectin family of proteins and the LOXL2 enzyme, and how both influence multiple biological pathways of these complex, often devastating, diseases. Galecto is funded by Novo Holdings, OrbiMed, Ysios, HBM Healthcare Investments, Sunstone Capital, M Ventures, Bristol-Myers Squibb, Maverick Ventures, Seventure and SEED Capital.

Our pipeline of clinical and preclinical studies covers a range of solid tumors and blood cancers. We have an active clinical trial for metastatic cancers that arise in the setting of an inherited BRCA1, BRCA2, or PALB2 mutation.

GENFIT is a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases characterized by high unmet medical needs. GENFIT is a pioneer in liver disease research and development with a rich history and strong scientific heritage spanning more than two decades. Its capacity to develop high potential assets, from early-stages to late development and pre-commercialization stages, is illustrated through the successful 52-week readout of its Phase 3 trial (ELATIVE®) evaluating elafibranor in Primary Biliary Cholangitis (PBC). Today, GENFIT has a diversified R&D pipeline covering several therapeutic areas: five programs in acute on chronic liver failure (ACLF) are in clinical stages (Phase 2) and pre-clinical stages, including hepatic encephalopathy (HE), one of the main complications of ACLF; a Phase 2 clinical program targeting cholangiocarcinoma; and a preclinical program targeting urea cycle disorders (UCD) and organic acidemias (OA). GENFIT’s pipeline also includes a diagnostic franchise focused on Metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis or NASH) and ammonia. GENFIT has facilities in Lille and Paris (France), Zurich (Switzerland) and Cambridge, MA (USA). GENFIT is a publicly traded company listed on the Nasdaq Global Select Market and on compartment B of Euronext’s regulated market in Paris (Nasdaq and Euronext: GNFT). In 2021, IPSEN became one of GENFIT’s largest shareholders and holds 8% of the company’s share capital.

Gila Therapeutics is a Boston-based clinical stage biotech company exploiting a novel, highly-targeted neural signaling system for the treatment of obesity, type 2 diabetes and associated metabolic disorders. Our innovative Topical Lingual Neural Signaling platform facilitates the direct activation of specific brain regions responsible for metabolic regulation through the delivery of natural peptide hormones without expectation of side effects. Our scientific advisory team is renowned globally for their unrivaled experience and pioneering contributions to the fields of endocrinology, neuroscience, and metabolic nephrology. Reach out to learn more about us.

Granata Bio is a biopharma company focused on women's health and infertility. Our mission and focus is to create access for fertility patients by introducing new therapeutic solutions.

Guardian is an independent biotech enterprise specialized in discovery and development of aptamer therapeutics.

Halloran Consulting Group is a life science consulting firm providing strategic development, regulatory, quality, clinical, and organizational support to industry leaders in the pharmaceutical, biotechnology, and medical device sectors. Our consultants are subject matter experts with technical and strategic expertise, who deliver a tailored approach to each engagement, successfully propelling our clients to their next inflection point.

TARGETED THERAPIES FOR EVERYDAY USE: Hilltop Bio products are room-temperature stable, practical, and ready-to-go purified therapies containing specific levels of selected regenerative components like extracellular vesicles, exosomes, growth factors, cytokines and microRNA that studies have shown to be effective at minimizing inflammation and promoting healing.

Inspired by nature’s ability to regulate protein function to restore health, HotSpot Therapeutics is discovering new allosteric therapies with the ability to treat disease in new ways. Unlike conventional drug discovery, which focuses on targeting the active sites of proteins, HotSpot has developed a technology platform to uncover nature’s privileged regulatory hotspots – pockets remote from the active site that are critical to protein function. Our team is designing novel therapies directed at regulatory hotspots, allowing us to treat diseases with limited or no known treatment options. Hotspot medicines are superior to conventional therapeutics given their exquisite selectivity, potent in vivo pharmacology and attractive drug-like properties.

Human Metabolome Technologies (HMT) is a Japan-headquartered biotechnology company founded in 2003 and global leader in capillary electrophoresis-mass spectrometry (CE-MS) based metabolome analysis. We established our United States headquarters in Boston, MA in 2012 and have spent the last 8 years developing solutions for a broad range of research endeavors in pharma, biotech, and food production.

IDRx is a clinical-stage biopharmaceutical company dedicated to transforming cancer care with intelligently designed precision therapies. IDRx aims to address the limitations of today’s precision cancer medicines with highly potent and selective targeted therapies to stop key tumor escape mechanisms and prolong response to therapy. IDRx’s lead program is IDRX-42, designed to inhibit key genetic drivers and drug-resistant mutations of KIT in gastrointestinal stromal tumor (GIST). IDRx's pipeline also includes a second KIT inhibitor, IDRX-73. Founded in 2021, IDRx’s leadership team has extensive experience in drug development and collectively has been involved in the discovery, development, and commercialization of more than 10 approved drugs. To learn more, please visit www.idrx.com.

At IFM Therapeutics, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body’s first line of immunological response and an essential component of immune function.

Ikena Oncology, Inc., a targeted oncology company, focuses on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, a selective AHR antagonist; IK-412, a recombinant human kynurenine-degrading enzyme; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.

Imbria is a privately held, clinical stage company developing novel therapies for patients with life-altering cardiometabolic disorders. Our clinical stage pipeline is focused on restoring or improving the cell’s ability to produce energy in cardiovascular disorders where energetic impairment is a fundamental contributor to symptoms and functional deficits. The lead product candidate, ninerafaxstat, is currently in Phase 2 clinical development in three indications: nHCM, stable angina, and HFpEF. For additional information, please visit www.imbria.com.

Immuneering is a biopharmaceutical company with an emerging pipeline focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying its deep knowledge of translational bioinformatics to every stage of the drug development process. Immuneering has more than a decade of experience in translational bioinformatics and generating insights into drug mechanisms of action and patient treatment responses. Building on this experience, Immuneering has developed a disease-agnostic platform that enables the company to utilize human data, novel biology and chemistry, and translational planning to create and advance its wholly owned pipeline. Immuneering’s current development programs in oncology are focused on providing potential treatments for patients with solid tumors caused by mutations of oncologic signaling pathways, including the MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is designed to be a highly selective dual-MEK inhibitor that further disrupts KSR for the treatment of advanced solid tumors in patients harboring RAS mutant tumors. Additionally, Immuneering has six other oncology programs in the discovery stage that are designed to target either the MAPK or mTOR pathway, and two neuroscience programs in the discovery stage. For more information, please visit www.immuneering.com.

Innate Bio’s platform is based on an engineered fungal carbohydrate that stimulates the innate immune system—our body’s first response against fungal infections. These carbohydrates are covalently linked to tumor-targeting monoclonal antibodies, which attract pre-existing antibodies, activate the complement system, and ultimately recruit innate immune cells to kill the tumor cells. Innate Bio’s antibody-beta-1,6-glucan conjugate technology has been applied to several monoclonal antibodies targeting cancer peripheral proteins.

Contract research organization since 2009. High-end R&D and cGLP technical services in specialty drug formulation development. Learn more.

Intus Bio is using its proprietary high-resolution, high-throughput assay and analysis technology to identify bacteria and deliver answers about the microbiome, with unprecedented detail, accuracy and scale. The company is powering groundbreaking research, discovery and services with clients and partners across the global pharmaceutical, diagnostic, and testing industries; is active in health, agricultural, and environmental fields; and continues to develop new and innovative partnerships, technologies, and applications.

At Ironwood Pharmaceuticals (NASDAQ: IRWD) our vision is clear: to bring new, differentiated therapies to the millions of patients who live with GI diseases. Building on a strong, decades-long foundation, the next leg of our journey continues with two innovative assets. Our in-market product, LINZESS® (linaclotide), discovered in-house, is the branded prescription market leader in its class. We are also pioneering the science behind our development program IW-3718 which aims to address highly symptomatic GI conditions with significant unmet needs. Ironwood was founded in 1998 out of the Whitehead Institute for Biomedical Research, an affiliate of Massachusetts Institute of Technology (MIT), and we remain headquartered in the vibrant biotech community of Cambridge, Mass. Each of our employees holds equity in the company, which means we all share the responsibility to help Ironwood succeed.

Ischemix is a privately-held pharmaceutical company that has developed novel cytoprotective compounds for the prevention and treatment of serious conditions of the kidney, heart and other organ systems.

iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of tumor immunology and immunosuppressive pathways to design novel product candidates with the potential to restore the immune response against cancer. The Company’s innovative pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways designed with optimized pharmacologic properties for improved clinical outcomes, including the TIGIT/CD226 axis and the adenosine pathway. iTeos Therapeutics is headquartered in Watertown, MA with a research center in Gosselies, Belgium.

Jordi Labs was founded in 1980 to provide the highest quality analytical services, polymer based HPLC columns and packing media in the industry. As a family company, we take pride in the production of each of our products. Customers in nearly all industries are currently using our columns, packing media, and SPE products worldwide. It is our goal to help our customers overcome their analytical challenges by providing excellent products and personal assistance from our highly trained staff. Jordi Labs provides contract analytical services with a special emphasis on chemical identification and liquid chromatography products. Products We manufacture a complete line of polymer-based high-pressure liquid chromatographic (HPLC) columns and gels for all types of applications including size exclusion (SEC) and solid phase extraction (SPE) cartridges. Analytical Service The service laboratory at Jordi provides extensive and specialized analytical testing of polymers, additives and other small molecules. Typical projects include product failure analysis, HPLC method development, polymer filler and additive quantitation, and unknown identification. Other services include method development, prep HPLC, training, depositions and consulting. Our two-fold business of providing services, as well as products, is especially qualified to meet the demands of the polymer industry.

Kailera Therapeutics (Kailera) (previously Hercules CM NewCo) is developing a broad, advanced, and differentiated portfolio of clinical-stage injectable and oral therapies for the treatment of obesity and related conditions. Kailera’s most advanced program, KAI-9531 (being developed in China as HRS9531), is an injectable GLP-1/GIP receptor dual agonist that demonstrated positive results in Phase 2 trials in obesity and type 2 diabetes in China. The Company is also advancing a diversified pipeline leveraging several mechanisms and routes of delivery, including oral administration. Kailera’s mission is to develop next-generation weight management therapies that give people the power to transform their lives and elevate their overall health.

Weaving along Hawaii's Na Pali Coast is the famous, breathtaking Kalalau trail. This trail is not only notable for its strenuous path and terrain that is difficult to traverse, but also known for its unsurpassed beauty. Kalalau was early inspiration for us, today representing our innovative spirit and deep commitment to advancing the treatment of eye diseases. KALA BIO is a clinical-stage biopharmaceutical company dedicated to the research and development of innovative therapies for rare and severe diseases of the eye. KALA BIO’s biologics-based investigational therapies utilize KALA BIO’s proprietary mesenchymal stem cell secretome (MSC-S) platform. KALA BIO’s lead product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. KPI-012 is currently in clinical development for the treatment of persistent corneal epithelial defect (PCED), a rare disease of impaired corneal healing, for which it has received Orphan Drug and Fast Track designations from the U.S. Food and Drug Administration. KALA BIO is also targeting the potential development of KPI-012 for the treatment of Limbal Stem Cell Deficiency and other rare corneal diseases that threaten vision and has initiated preclinical studies to evaluate the potential utility of its MSC-S platform for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease. For more information on KALA BIO, please visit www.kalarx.com.

Kalion was founded to take on the significant challenge of commercializing important new molecules that could be derived in a greener manner and offer significant advantages over traditional oil-based molecules. Prof. Kristala Prather at MIT decided using the Department of Energy's Top Value-Added Chemical from Biomass Report that glucaric acid offered a significant challenge but if successful it could offer a new platform chemical that could would have much to offer the world. Her success, with glucaric acid and the subsequent development at Kalion has created a high purity glucaric acid that now allows companies and researchers from other universities to fully exploited the unique properties of glucaric acid and related molecules.

KalVista Pharmaceuticals is a biopharmaceutical company developing oral medicines designed to empower people to enjoy everyday life beyond the challenge of their disease. We apply our expertise to discover, develop and commercialize oral protease inhibitor drugs based on deep expertise in the kallikrein-kinin system. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with sebetralstat, our first investigational product for hereditary angioedema (HAE), a rare genetic disease with debilitating attacks of tissue swelling that can be life threatening.

Karyopharm Therapeutics Inc. is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. As an organization, Karyopharm is on a mission to improve lives and defeat cancer. In its role as leaders in XPO1 inhibition, Karyopharm delivers on its mission by creating a focused pipeline that targets multiple high unmet need cancer indications, including multiple myeloma, endometrial cancer, myelofibrosis, and diffuse large B-cell lymphoma (DLBCL).

KBioBox is a Bioinformatics company that specializes in fast precision Off Target Analysis and Gene Edit BioDesign for genetic data.

Keros is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from rare hematologic and musculoskeletal disorders with high unmet medical need.

Kiniksa is a publicly traded biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutic medicines designed for patients suffering from debilitating immunological diseases with significant unmet medical need. We have a pipeline of product candidates across various stages of development, focused on autoinflammatory and autoimmune conditions. We are relentless and focused on patients and strive to develop life-changing medicines. We are focused on hiring and retaining a highly skilled team that has extensive experience and specific skill sets relating to the selection, development, and commercialization of transformative therapies. Whether in development, research, manufacturing, technical operations, or general / administrative functions, we depend on a brilliant team to support our mission of building a global, generational company.

Kira Pharmaceuticals is a clinical-stage, global biotechnology company pioneering a world free from complement disease. Enabled by its LOGIC platform, the company has developed a robust pipeline of nine (9) novel complement assets focused on validated targets across the complement cascade. With an experienced team of complement biology experts, drug developers, protein engineers and leaders from across the pharma and biotech industry, Kira Pharmaceuticals is uniquely positioned to tackle some of the most complex and toughest challenges in the complement space and to deliver first-in-class and best-in-class therapies to transform the lives of patients. The company is headquartered in Cambridge, Massachusetts with offices in Suzhou and Shanghai, China, and Australia.

KSQ Therapeutics has built an industry-leading genome-scale precision functional genomics platform, called CRISPRomics, to pinpoint therapeutic nodes that directly correlate genomic function to disease with unprecedented certainty and speed. The company is deploying CRISPRomics for novel drug development across broad therapeutic areas and is currently advancing a proprietary pipeline of tumor- and immune-focused drug candidates.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.

Lantheus Holdings, Inc. (NASDAQ: LNTH) is the parent company of Lantheus Medical Imaging, Inc. (LMI), which is a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, which are primarily used for the diagnosis of cardiovascular diseases. LMI’s key products include the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs.

Leukemia Therapeutics is a biotech company that discovers and brings leukemia drugs to market. The company focuses on Acute Myeloid Leukemia (AML),

Lucy Therapeutics is offering a differentiated and novel approach to drug discovery by drugging targets associated with early disease pathogenesis. LucyTx’s unique approach recognizes that improvement of mitochondrial function early in disease will lead to disease modification as opposed to late-stage symptomatic treatments being pursued by many others. Mitochondrial improvement effects multiple downstream effectors that are essential to disease initiation and progression. Our targets have been validated as neuroprotective in multiple animal models. Key to our strategy is a novel dosing regimen which will mimic effects known to be protective for both neurological and cardiovascular events implicated in key CNS diseases. LucyTx proposes to focus on the orphan disease Rett Syndrome for a proof of concept; we will also explore applications of our technology to Parkinson’s and other CNS diseases.

Welcome to Lyndra Therapeutics: Medicine, reinvented Imagine taking a week’s worth of medicine in a single dose, once a week. Four pills a month. Eventually, one pill a month. Lyndra Therapeutics’ LYNX™ drug delivery platform is making that possible. Lyndra Therapeutics is a clinical-stage biopharmaceutical company pioneering long-acting oral therapies. Lyndra is focused on commercializing therapies in central nervous system (CNS) disorders, with lead product candidate oral weekly risperidone (LYN-005) for the treatment of people living with schizophrenia and bipolar 1 disorder. The company is also committed to advancing its platform to tackle major public health and global health challenges, with therapies including oral weekly levomethadone and oral weekly buprenorphine for opioid use disorder, a monthly oral contraception pill and oral biweekly ivermectin for malaria eradication. Since its founding, partners have included the Bill & Melinda Gates Foundation, the NIH, AbbVie and Gilead Sciences, Inc. Lyndra is headquartered in Watertown, MA and has a state-of-the-art GMP manufacturing facility in Lexington, MA. Core purpose: reinvent medicine for a healthier world Core values: value every voice; resilient to the core; I contribute, we deliver

Lytica Therapeutics is a Cambridge-based biotech company developing novel peptide conjugates for next-generation ADCs. The secret to unlocking more effective ADCs is in the...

Magnet Biomedicine’s modular TrueGlue™ technology enables the systematic discovery of molecular glues towards the treatment of human disease.

Matchpoint is a biotechnology company harnessing the power of covalency to discover precision covalent medicines to transform the treatment of immune diseases and other serious illnesses. The company's proprietary Advanced Covalent Exploration (ACE) platform integrates advanced chemoproteomics, machine learning and covalent chemistry library evolution. Matchpoint has an emerging pipeline of novel covalent medicines initially focused on immunology. For more information, please visit www.matchpointtx.com.

MatTek Life Sciences is at the forefront of tissue engineering and is a world leader in the production of innovative 3D reconstructed human tissue models. Our skin, ocular, and respiratory tissue models are used in regulatory toxicology (OECD, EU guidelines) and address toxicology and efficacy concerns throughout the cosmetics, chemical, pharmaceutical and household product industries. With facilities in the U.S. and Slovakia, MatTek's human cell-derived tissue models are widely used in the United States, Europe and Japan. Our record of scientific and technological innovation remains strong as we continue to develop and validate new in vitro assays, human tissue models and optically advanced cultureware. We invite you to use our products, services and technical solutions, which will afford your company new opportunities in obtaining faster, cost-effective, more reliable and human-relevant results compared to the traditional assays and 2D in vitro systems.

MelliCell develops therapeutics for diabetes and obesity using proprietary technologies that model of weight gain in human fat cells in vitro. Our core technology enables discovery of therapeutic targets and leads, while reducing the time and money required for efficacy screening. It efficiently turns human stem cells into fat cells and accelerates their growth to sizes that are thousands of times larger than conventional limits and that match the sizes of mature fat cells in adults. Changes in fat cell size are how adults gain (or lose) weight, and increased fat cell size predicts diabetes better than obesity per se. The products we develop will treat obesity and diabetes by shrinking fat cell size and by preventing compromised metabolism in enlarged cells. We differentiate ourselves from existing therapies (e.g. GLP-1 analogs, SGLT2 inhibitors, anorexiants, intestinal lipase inhibitors, insulin secretagogues) by focusing on adipocyte-intrinsic mechanisms of action enabled by our core technology.

MetaVia (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is currently developing DA-1726 for the treatment of obesity and DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for once-a-week injection. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, potentially resulting in superior body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-protein-coupled receptor 119 (GPR119) agonist that promotes the release of key gut peptides GLP-1, GIP, and PYY. In pre-clinical studies, DA-1241 demonstrated a positive effect on liver inflammation, lipid metabolism, weight loss, and glucose metabolism, reducing hepatic steatosis, hepatic inflammation, and liver fibrosis, while also improving glucose control. Our strategic partner and the largest investor, Dong-A ST Co. Ltd., is part of the Dong-A Socio Group of companies established in 1932 and based in South Korea. MetaVia has the full support of Dong-A ST’s Research Center, providing the company with access to R&D, scientific and CMC expertise.

The METiS platform (AiTEM) combines state-of-the-art AI data-driven algorithms, mechanism- driven quantum mechanics and molecular dynamics simulations to calculate Active Pharmaceutical Ingredient (API) properties, elucidate API-target and API-excipient interactions, and predict chemical, physical and pharmacokinetic properties of small molecule and nucleic acid therapeutics in specific microenvironments. This enables efficient lead optimization, candidate selection and formulation design. Founded by a team of MIT researchers, serial entrepreneurs and biotech industry veterans, METiS develops and in-licenses novel assets with high therapeutic potential that could benefit from its data-driven platform.

Metro International Biotech, LLC is a privately-owned clinical-stage pharmaceutical company that has established the most comprehensive portfolio of proprietary drugs for the treatment of various diseases.

Minerva Biotechnologies is a clinical stage biopharmaceutical company focused on developing immunotherapies for solid tumor cancers and cellular therapies for regenerative medicine. NCT04020575 is Minerva’s first-in-human trial of huMNC2-CAR44, a CAR T that targets the MUC1* growth factor receptor, for the treatment of metastatic breast cancers, 95% of which express a MUC1*. We are now expanding the current clinical trial to include our second CAR-T product that greatly increases persistence. The Company is rapidly accelerating its pipeline that includes next-gen CAR-T products, a straight antibody therapeutic and a small molecule therapeutic which are both for the treatment of cancer metastasis. Our track record of scientific breakthroughs is a testament to our visionary team and our collaborative culture. Join us in changing the world.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of a portfolio of product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options.

"We are developing next-generation therapies to treat neurological disorders. Patients first: Our lead small molecule is a GABA-A modulator targeting Essential Tremor (ET), fine-tuned to restore healthy receptor function while avoiding excessive receptor activation. This allows for preserved efficacy and reduce side-effects. We achieved preclinical in vivo proof-of-concept, and are now identifying a lead clinical candidate. Following, we plan to develop therapies for anxiety and epilepsy. "

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body’s natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn’s disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is based in Boston, Massachusetts.

Oral integrin therapies for patients with immunological, fibrotic, neoplastic and vascular diseases. Morphic Tx is joining a three decade quest led by our scientific founder, Tim Springer, who initially discovered the integrin receptor family in the 1980s. This receptor family is an important drug target that has fueled the successful development of six injectable therapies approved for treatment of multiple sclerosis, ulcerative colitis, Crohn's disease, plaque psoriasis, acute coronary syndrome and complications during percutaneous coronary intervention. Despite blockbuster commercial success, integrins have remained out of reach as small molecule drugs...until now.

Developing therapeutics to address the unmet need and societal burdens posed by neurodegenerative, demyelinating and neuropsychiatric disorders.

Mythic Therapeutics is a product-platform company that is pioneering a powerful new approach to improving the effectiveness of antibody-drug conjugates (ADCs) and other antibody-based therapeutics. Our technology dramatically increases therapeutic potency without compromising safety, thereby unlocking the full potential of targeted therapies against a broad array of tumor targets. At Mythic, we focus on patient-centered science and are driven to leave a lasting impact on cancer care.

Nereid starts with approaches to see and measure the biomolecular forces driving phase separation, amplifying insights with machine learning, and accelerating translation with cell biology and medicinal chemistry. Nereid’s platform uses physics to discover therapeutics that can modify the phase behavior of livingcells.

We are Nested Therapeutics, a biotech company inspired by service and driven by a desire to make a meaningful impact. We are creative innovators who challenge our own assumptions as we strive to find new, overlooked areas of opportunity to design therapeutics for a perfect fit. We embrace diverse perspectives and experiences in a space for everyone to add value and be valued in return, with the purpose of building solutions together while having fun doing it. United through our common vision for the future of precision medicine and our shared values of service, humility, impact, invention, and connection, we’re determined to dramatically expand the reach of precision medicine and make first- and best-in-class precision oncology treatments available to a larger population.

Brain diseases collectively represent one of the largest areas of unmet medical need, affecting upwards of 1.5 billion patients globally. Neumora was founded to confront the global brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. Our goal is to redefine neuroscience drug development by bringing forward the next generation of novel therapies that offer improved treatment outcomes and quality of life for patients. We’ve built a pipeline comprised of programs for neuropsychiatric disorders and neurodegenerative diseases, each targeting a novel mechanism of action where we can leverage our precision neuroscience approach. Our pipeline currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Neumora is committed to addressing some of the most prevalent brain health disorders and transforming the standard of care for millions of patients living with brain diseases. Learn more about Neumora and career opportunities on our website below.

Neuphoria Therapeutics Inc. is a clinical-stage biopharmaceutical company based in Burlington, Massachusetts. Formerly known as Bionomics Limited, the company focuses on developing innovative therapies for neuropsychiatric disorders and cancers. Neuphoria was incorporated in 1996 and rebranded in December 2024. The company's lead product candidate, BNC210, is a selective negative allosteric modulator aimed at treating social anxiety disorder and post-traumatic stress disorder (PTSD). BNC210 is currently in Phase 3 and Phase 2b clinical trials, respectively. Other products in development include BNC101, a monoclonal antibody for cancer stem cells, and BNC105, which targets refractory colorectal cancer and chronic lymphocytic leukemia. Neuphoria is also exploring treatments for cognitive deficits in schizophrenia and autism spectrum disorders, as well as chronic pain management without opioid addiction. The company has partnered with Merck & Co., Inc. to develop therapies for cognitive dysfunction related to Alzheimer's disease and other central nervous system conditions.

NeuroCores Inc. is a preclinical-stage biopharmaceutical company focused on developing treatments for rare pediatric neurological disorders and neurodegenerative diseases. The Company's lead product candidate, KIT-13, is undergoing nonclinical studies for Rett Syndrome and other neurodegenerative diseases, and it has been granted both Rare Pediatric Drug Designation and Orphan Drug Designation from the US FDA for treating Rett syndrome. Additionally, NeuroCores has two more compounds, KIT-18 and KIT-20, for RCDP and Leigh Disease, respectively. NeuroCores's innovative plasmalogen derivatives have the potential to treat many more CNS disorders because of their potent anti-neuroinflammatory and neurogenesis effects.

Neuronity is a biotech company dedicated to revolutionizing the treatment of neurodegenerative diseases. With a focus on age-related neurological disorders, such as Parkinson's disease, our cutting-edge gene and cell therapy approach aims to restore healthy immune cell function in aging brains. By targeting the root causes of these conditions, we strive to reduce the unmet needs of patients, families, and caregivers. Our mission is to improve the quality of life for individuals affected by neurodegenerative diseases through groundbreaking interventions and strategic collaborations. Join us in shaping the future of CNS disease therapeutics and making a lasting impact on the lives of millions. #Neuroscience #Biotech #GeneTherapy #CellTherapy #NeurodegenerativeDiseases

NeuroNOS is a pioneering biopharmaceutical company developing a novel drug for Autism Spectrum Disorder (ASD) and other neurological conditions. The company’s small-molecule therapy is based on a technology from the Hebrew University. It is designed for subcutaneous injection or oral administration and aims to regulate nitric oxide (NO) levels in the brain, a mechanism that has shown significant promise in preclinical studies. NeuroNOS has demonstrated that balancing NO levels can lead to both behavioral and biological improvements in animal models of autism. The company is actively advancing its preclinical research, with plans to enter a Phase 1 human clinical trial in 2026.

We are dedicated to providing a new dawn or "eos" for patients with mental health conditions by developing next generation, first- and best-in-class therapies. Over 100 million patients in the United States are affected by neuropsychiatric disorders, with anxiety and substance use disorders among the largest areas of unmet medical need. Our clinical-stage pipeline was licensed from Roche and includes oral small molecules targeting GABAA-γ1, V1a, TAAR1 and GABAA-α5 with broad potential in general anxiety, social anxiety, substance use disorders and cognitive impairment. Newleos was co-founded by Longwood Fund, Federico Bolognani, M.D., Ph.D., and William Martin, Ph.D., seasoned experts in company creation and CNS drug development.

NextRNA focuses on lncRNAs, which account for the majority of ncRNAs. Their approach is motivated by observations where disregulated interactions between lncRNAs and RNA-binding proteins (RBPs) are implicated in multiple disease areas, including oncology, immunology, and neurology. They are elucidating the proteins that lncRNAs interact with and what cellular processes they affect and designing small molecules to drug these lncRNA-RBP interactions.

Nido Bio is translating today’s neuroscience breakthroughs into tomorrow’s treatments for severe neurological diseases. Leveraging human genetics, we develop precision medicines that address the fundamental biology of disease and restore healthy cell function. NIDO-361, our clinical-stage candidate, is a treatment for Spinal and Bulbar Muscular Atrophy which is a rare and debilitating neuromuscular disease. Additional pipeline programs center around a novel target with the potential to address multiple disease mechanisms and that has broad clinical application across neurodegenerative and peripheral inflammatory diseases. We are creating a sustainable pipeline for the company by utilizing a functional genomics discovery platform based on human cell lines to identify novel targets. Through our approach we seek to transform patient lives in meaningful ways.

Nocion Therapeutics is a biopharmaceutical company that is revolutionizing the treatment of conditions arising from neurogenic inflammation. The company is developing novel treatments for silencing neurons using a platform of unique molecular entities. Nocion Therapeutics is also focused on developing novel small molecule CSCBs, known as 'nocions', to address medical conditions related to neurogenic inflammation.

NodThera is developing a new class of potent and highly selective NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. We’re building a dynamic team of people across our offices in Cambridge, UK; Seattle, WA; and Boston, MA; all united by our shared ambition, enthusiasm, and creativity.

Nuvalent, Inc., a preclinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors; and NVL-655, a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third generation ALK inhibitors. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Discovering new medicines based on metabolic vulnerabilities in pathological cell populations. Underlying platform uses engineered growth conditions to highlight novel metabolic targets in disease-causing bacteria, lymphocytes, and metastasizing cancer cells. Lead programs in autoimmunity and infectious disease.

At Odyssey, we are creating next generation precision medicines for patients with cancer and inflammatory diseases with class-leading speed, efficiency and rigor through our highly integrated drug hunting engine. In response to recent recruitment fraud, visit our Careers page to verify all job opportunities and read our guidance on this topic: https://odysseytx.com/careers/

ORGANIX, has recently joined the Symeres family which begins an exciting new chapter for employees on both sides of the Atlantic and for customers, new and existing, across the globe. The two companies come together as perfect partners in delivering exciting, exceptional services and an unmatched enthusiasm for organic chemistry. ORGANIX a Massachusetts based corporation established in 1986, conducts research and development under contract in organic chemistry and all related areas. The company is located about thirty minutes from downtown Boston and Logan International airport. ORGANIX can assist you in the pursuit of your research and development goals. ORGANIX provides a cost effective and confidential means of carrying out short and long term synthetic chemistry without the need to hire additional scientists. The Company's highly trained staff can attend to your needs (milligram to kilogram) in a timely and professional manner. Symeres is one of Europe's largest small molecule CRO (Contract Research Organization) and CDMOs (Contract Development and Manufacturing Organization) Headquartered in the Netherlands it has a headcount of about 600 working at locations in the Netherlands, the Czech Republic, and the Nordics. Around 60% hold a PhD

Orionis Biosciences is a life sciences company pioneering technological innovation in genome-scale drug discovery and tunable molecular design of novel therapeutic drug modalities. Our technologies and pipeline include proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms with broad, innovative applications to the reprogramming of disease states. The company is currently advancing multiple novel immunotherapies for the treatment of cancer.

Orthogon Therapeutics is a drug development company focused on designing innovative antivirals and anti-infectives. Their initial focus is on treating BK and JC polyomavirus infections in transplant patients.

Orum Therapeutics is a private, clinical stage biotech pioneering the development of tumor-directed targeted protein degraders by leveraging its TPD² approach to provide dual-precision, antibody-enabled targeted protein degraders for cell-specific delivery. The Company’s proprietary platforms generated using the TPD² approach include the GSPT1 platform, which generates first-in-class antibody drug conjugates. The first therapeutic candidates from the GSPT1 platform are in development for the treatment of solid tumors and hematologic cancers. Orum is located in Boston, US and Daejeon, South Korea.

Oryzon Genomics, S.A. is a clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology. Oryzon has a broad and growing portfolio, with two compounds in clinical trials: iadademstat, a highly potent and selective LSD1 inhibitor, in Phase IIa clinical trials for the treatment of acute myeloid leukemia and small cell lung cancer, and vafidemstat, a CNS optimized LSD1 inhibitor in multiple Phase II trials for the treatment of CNS and psychiatric diseases. Phase IIb trials for both compounds are under preparation. Our pipeline also includes ORY-3001, a selective LSD1 inhibitor in preclinical development for the treatment of non-oncological diseases, and additional programs for developing inhibitors against other epigenetic targets. Oryzon has a strong technological platform for biomarker identification and performs biomarker and target validation for a variety of malignant and neurological diseases. Oryzon has been listed on the Spanish Stock Exchange since December 2015 (ORY, ISIN Code: ES0167733015). Since then, the company has attracted specialized investors from US, Israel and Europe in several PIPEs led by different US investment banks. The company was founded in 2000 and has offices in Spain and the United States.

Palleon Pharmaceuticals is the leading biotechnology company focused on developing Glyco-Immune Checkpoint inhibitors to treat cancer. The company’s proprietary Convergence Platform integrates technologies and insights from world-renowned scientific leaders in the fields of glycoscience and human immunology to create a novel approach to treating cancer. By targeting multiple immune cell types, Glyco-Immune Checkpoint inhibitors will tackle resistance to first-generation immuno-oncology agents, and make possible a wider range of rational combination therapies to treat cancer. While Palleon is focused primarily on oncology, the Convergence Platform is applicable to other therapeutic areas including infectious diseases, neurodegeneration, inflammation, and fibrosis. The company is advancing its pipeline and development programs with a $47.6 million Series A financing from leading biotech venture investors SR One, Pfizer Ventures, Vertex Ventures HC, Takeda Ventures, and AbbVie Ventures.

PAQ Therapeutics is a biotechnology company pioneering a new approach to restoring heath and curing disease through autophagy, the body's most versatile mechanism for natural cellular degradation. With our ATTEC (autophagosome-tethering compound) technology, we are developing a novel class of small molecule degraders capable of binding a diverse array of substrates to the autophagy pathway including proteins, aggregates, lipids, organelles and pathogens. PAQ's research advances in this important new class of degradation therapies have the potential to fundamentally transform drug discovery and development.

Parabilis Medicines™ is a clinical-stage biopharmaceutical company dedicated to creating extraordinary medicines for people living with cancer. Through our pioneering Helicon™ discovery platform, Parabilis is engineering precisely-tuned, stabilized helical peptide therapeutics that have the potential to unlock a large number of traditionally undruggable targets. FOG-001, our first-in-class TCF-blocking β-catenin inhibitor and lead clinical program, is being evaluated in a Phase 1/2 study for patients with colorectal cancer and other solid tumors and is proof of the applicability of our platform to address undruggable intracellular protein-protein targets. We are additionally advancing a pipeline of other first-in-class programs that target proteins known to be relevant to numerous cancers, but considered intractable with traditional drug modalities. The versatility of the Helicon approach allows for the discovery of multiple targeting mechanisms, including functional protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. We are headquartered in Cambridge, Mass., and are well-capitalized, with more than $500 million raised to date from leading life sciences investors. For more information, please visit: www.parabilismed.com

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris.

Parthenon Therapeutics is a Massachusetts-based biotechnology company that develops and commercializes novel therapies for the treatment of cancer.

Passkey Therapeutics is pioneering a new class of medicines, Synergistic Multifunctional Therapeutics or SMThs, designed to address complex diseases by targeting rare combinations of proteins that work together. Using its proprietary Locksmith platform, the company is advancing programs across multiple therapeutic areas to create new options for patients with common, hard-to-treat conditions.

For 85 years, PerkinElmer has pushed the boundaries of science in our food, industrial, life science and environmental markets. In addition to innovative laboratory technologies, our OneSource services division delivers a highly trained, experienced, and collaborative team of service engineers with solutions scalable and customizable to serve laboratory needs. We’ve always pursued science with a clear purpose – to help our customers achieve theirs. Our expert team brings technology and intangibles, like creativity, empathy, diligence, and a spirit of collaboration, in equal measure, to fulfill our customers’ desire to work better, innovate better, and create better. PerkinElmer is a leading, global provider of technology and service solutions that help customers measure, quantify, detect, and report in ways that help ensure the quality, safety, and satisfaction of their products. Science with Purpose. Learn more at www.perkinelmer.com.

PharmaLex is now part of Cencora, a leading global pharmaceutical solutions organization centered on improving lives around the world PharmaLex adds to Cencora's expanding suite of pharma solutions and serves the pharma, biotech, and medtech industries. We guide clients from early strategic planning activities and non-clinical requirements through clinical development, regulatory submission processes and post-approval / maintenance post-launch activities. Our experts use technology-elevated solutions to support clients through the entire product lifecycle. Learn more at http://www.pharmalex.com

Pharvaris is a clinical-stage company focused on bringing oral bradykinin-B2-receptor antagonists to patients. By targeting this clinically proven therapeutic target with novel small molecules, the Pharvaris team is advancing new alternatives to injected therapies for all sub-types of HAE and other bradykinin-mediated diseases. The company brings together executives with a breadth of expertise across pharmaceutical development and rare disorders, including HAE. The company reunites the core team responsible for the discovery and approval of the HAE treatment icatibant. With novel small molecules, we have identified and are advancing potent, orally available compounds targeting this clinically proven therapeutic target.

Phio Pharmaceuticals Corp. (Nasdaq: PHIO) is a clinical stage biotechnology company whose proprietary INTASYL™ RNAi technology makes immune cells more effective in killing tumor cells. INTASYL is the only self-delivering RNAi technology focused on immuno-oncology therapeutics. INTASYL drugs precisely target specific proteins that reduce the body’s ability to fight cancer, without the need for specialized formulations or drug delivery systems. Phio was co-founded by Nobel Laureate Craig Mello, who was awarded the Nobel prize in 2006 for his discovery of RNAi, which has broad therapeutic applications. Our founders opened up a whole new field of biology when they discovered RNAi, and we continue their pioneering efforts today through our work with INTASYL. We’re committed to discovering and developing innovative cancer treatments for patients, creating new pathways for a cancer-free future. For additional information, visit the Company's website, www.phiopharma.com. #INTASYL #siRNA #RNAi #Phio #immunooncology

Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases and immuno-oncology multi-specifics tailored for the tumor microenvironment. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies.

Pion supports drug development programs with in vitro scientific instruments, contract research, and equipment maintenance. All designed to support more informed, more accurate, more timely decision making. Pion’s range of scientific instruments and services provide innovative solutions to the challenges of in vivo prediction, phys chem analysis, dissolution, and more. Clients may access Pion’s expertise either through the purchase of our instruments, or by contracting with our laboratories to run screens, assays and analysis on their behalf. Please contact sales@pion-inc.com or visit our website www.pion-inc.com

Pledge Therapeutics efforts have given rise to a constellation of exciting discoveries, spanning from early drug hits to preclinical candidates. Our success is based on the rapid translation of clinical and disease insights into target identification and development of novel drug molecules. At the core of our effort is the integration of structural and biophysical knowledge of disease targets to accelerate the pace and success of drug development.

Praesidia Biotherapeutics is built with the vision of being a patient focused and clinician driven drug development company championing unmet clinical needs. Praesidia's proprietary first in class Tunable Linker Technology is revolutionizing the ways to maximize.

Prana BioSciences Inc., is an early-stage hybrid biotech and biomanufacturing company. We envision a world where all people living with a disease that can be best treated with a biologic should have access to one. Our steadfast mission is to develop, and manufacture cost-effective "biobetter" versions of the world's most successful monoclonal antibodies (mAbs) for a broader patient population. We are a biotech merging robust, established best-practice antibody development practices with advanced AI-supported enhancements in binding, function, and patient safety. We have our own identified four “biobetter” versions of the world's most successful monoclonal antibody targets, which come with new intellectual property. Along with serving as a catalayst for governments, to build a bio-tech development hub, we also have a biomanufacturing center with a proprietary manufacturing platform featuring our own vector, cell line, and processes to develop customized therapeutic mAbs for itself and offer excess capacity as Contract Development & Manufacturing Organization (CDMO) services to other biotech firms. And to achieve our patient ambition we have a seasoned leadership team of inventors, scientists, commercial specialists and big thinkers combining deep expertise to develop, register, manufacture and commercialize antibody-biobetters in a quest to deliver life-transforming medicines that can profoundly impact patients’ lives.

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance. Praxis is applying insights into the genetic mutations that drive excitation-inhibition imbalance in diseases to select biological targets for rare and more prevalent neurological disorders. We share a common vision of reshaping the human condition into a more freeing and fulfilled existence by developing high impact medicines for patients and families affected by and living with complex brain disorders. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain.

Pretzel Therapeutics is leading the way for a new era of life-changing medicines for patients and families affected by mitochondrial disease. The company's mission is to develop groundbreaking therapies to reverse mitochondrial dysfunction through mitochondrial biology.

Prilenia is a clinical-stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders. Our lead asset is Pridopidine, a first-in-class oral drug candidate with an established safety profile and potential in multiple movement disorders and neurodegenerative diseases affecting adults and children. Pridopidine is currently being evaluated for the treatment of Huntington’s disease in our global Phase 3 PROOF-HD trial, and for the treatment of ALS in the Phase 2/3 HEALEY platform trial. The company is led by Dr. Michael Hayden, MD, PhD, the founder of five biotech companies and previous President of Global R&D and Chief Scientific Officer at Teva. Michael has directed the development of multiple innovative drug products, leading to 35 approvals between 2012-2018. The Company is based in Naarden, the Netherlands, Herzliya, Israel and Boston, MA in the U.S.

Promakhos Therapeutics is an Allston-based biotech startup founded in the spring of 2021. The company aims to develop curative therapies that restore the body's innate ability to fight inflammatory disorders. Promakhos Therapeutics focuses on creating therapies for autoinflammatory diseases based on a new and unexplored mechanism.

PULMATRIX is committed to the development and commercialization of novel and transformational medicines for patients all over the world, using our proprietary iSPERSE™ technology to optimally deliver both respiratory and non-respiratory therapies via the respiratory system.

PureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep pipeline through its experienced research and development team and its extensive network of scientists, clinicians and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 27 therapeutics and therapeutic candidates, including two (Plenity® and EndeavorRx®) that have received both US FDA clearance and European marketing authorization and a third (KarXT) that has been filed for FDA approval. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration enabling studies. All of the underlying programs and platforms that resulted in this pipeline of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points.

At Qlaris, our lead program is QLS-111, a novel topical ocular therapy that lowers intraocular pressure with a unique mechanism of action. QLS-111 is distinct from currently available therapies by selectively targeting episcleral venous pressure (EVP) and improving outflow distal to the trabecular meshwork. This novel mechanism may enable the improved treatment of diseases where EVP has limited therapy or has itself been pathologic, such as Normal Tension Glaucoma, Primary Open Angle Glaucoma, glaucoma associated with Sturge-Weber Syndrome, and also in combination with Minimally-Invasive Glaucoma Surgery (MIGS) devices.

We are a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius' lead product, TYMLOS® (abaloparatide) injection was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes investigational abaloparatide injection for potential use in the treatment of men with osteoporosis; an investigational abaloparatide patch for potential use in osteoporosis; and the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer out-licensed to Menarini Group.

Rapport Therapeutics aims to transform the treatment of neurological disorders through a precision medicine approach, precisely targeting disease-driving neurocircuits by leveraging receptor-associated proteins (RAPs). With this approach, Rapport can overcome the well-established limitations of today’s neuromedicines that act indiscriminately throughout the nervous system, resulting in suboptimal efficacy and burdensome side effects. Leading the hunt for precision medicines is a team with established track records of innovation in neuroscience and drug discovery. Rapport was conceptualized and created through a partnership between Third Rock Ventures and Johnson & Johnson Innovation-JJDC, Inc. (JJDC) and launched in March 2023. Rapport is based in San Diego, CA and Boston, MA. For more information, please visit www.rapportrx.com.

A discovery through early clinical phase pharmaceutical company, Ratio Therapeutics employs a suite of innovative technologies to develop best-in-class targeted radiotherapeutics for the treatment of cancer. Ratio Therapeutics’ Trillium™ targeting scaffold combines pharmacokinetic modulation with best-in-class chelation technology to create proprietary small molecule targeting agents to attack a broad array of cancer targets. Our compounds accommodate imaging and therapeutic radioisotopes, ie "theranostics". The tunable nature of our platform combined with small-scale imaging trials in patients results in accelerated, de-risked compound selection.

Rectify develops Positive Functional Modulators (PFMs), a novel class of oral, small molecules that restore and enhance membrane protein function to address the underlying cause of serious diseases. PFMs have the potential to modulate the activity of wild-type and mutated membrane bound proteins. The Rectify platform enables efficient and rapid discovery of first- and best-in-class small molecule therapeutic candidates for the treatment of rare and common diseases, including liver, cardio-renal-metabolic, and neurodegenerative diseases. Rectify was founded and seeded by Atlas Venture who co-led the $100M Series A round with Omega Funds and were joined by Forbion and Longwood Fund.

Relay Therapeutics is a clinical-stage precision medicines company transforming the drug discovery process. Built on unparalleled insights into protein motion and how this dynamic behavior relates to protein function, our approach combines unprecedented computational power with leading-edge experimental approaches across the fields of structural biology, biophysics, chemistry and biology. By applying these insights, we believe we have a differentiated approach to drug protein targets based on their motion, enabling us to select and advance unique product candidates that can be developed into novel therapies for patients. Located in Cambridge, Massachusetts, our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. If you're creative, collaborative and passionate about making a difference in the lives of patients, join us!

Remix launched in 2020 with a vision to transform patient's lives through modulation of RNA processing. Our breakthrough science provides a path to identify small molecules that impact the expression of disease driving mRNAs and proteins. We take on the challenge of addressing drug targets in diseases of high unmet medical need to bring new therapeutic options to patients. Remix has a commitment to demonstrate the highest levels of scientific integrity with urgency because those patients are counting on us to deliver. With an in-house technology platform built from scratch, we have rapidly generated multiple drug discovery programs that are advancing towards the clinic.

Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity. The company recently announced topline results from pivotal Phase 3 clinical trials in POMC deficiency obesity and LEPR deficiency obesity. Rhythm is also conducting a pivotal Phase 3 trial in Bardet-Biedl syndrome and Alström syndrome. The company is leveraging the Rhythm Engine -- comprised of its Phase 2 basket study in additional rare genetic disorders of obesity, TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of these disorders. For healthcare professionals, visit www.UNcommonObesity.com for more information.

Riparian Pharmaceuticals is an early stage biotechnology company employing innovative models of vascular pathophysiology to discover novel therapeutics In nature, the riparian zone is a unique rich ecosystem created through the interaction of a river with its banks. In the human body, moving blood, or hemodynamics, similarly interacts with the walls of blood vessels generating unique biological activity. This very interaction, between hemodynamics and the vascular wall, is a critical and unexplored determinant of vascular health. Riparian is deploying hemodynamics as a tool to discover first in class therapeutics acting on new pathways at an earlier stage of disease than is possible today.

Romeg Therapeutics is an innovative biopharmaceutical company with a focus on targeting high unmet need indications historically overlooked by the pharmaceutical industry.

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes novel medicines to treat central nervous system (CNS) disorders. Its lead product candidate is ZULRESSO, a proprietary intravenous formulation of brexanolone for the treatment of postpartum depression (PPD). The company’s product pipeline also includes SAGE-217, a novel neuroactive steroid, which is in Phase III clinical trials for treating PPD, major depressive disorders, bipolar depression, and generalized anxiety disorders; and SAGE-324, a novel compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epileptiform disorders and Parkinson’s diseases. In addition, its product pipeline comprises SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which has completed Phase I clinical trial for the treatment of depression, Huntington’s disease, Alzheimer’s disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. Further, the company is developing SAGE-904, an oral therapy that is in Phase I clinical trial for disorders associated with NMDA hypofunction; and SAGE-689 for intramuscular administration. Sage Therapeutics, Inc. has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of SAGE-217; Biogen Inc. to develop and commercialize zuranolone (SAGE-217) for various depressive disorder, postpartum depression, and other psychiatric disorders, as well as SAGE-324 for essential tremor and other neurological disorders; and Biogen MA Inc. and Biogen International GmbH for the development, manufacture, and commercialization of products containing SAGE-217 molecule and products containing the SAGE-324 molecule. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Samsara Therapeutics, Inc. is biopharmaceutical company aiming to discover first-in-class therapeutics that treat rare genetic and neurodegenerative disease, and extend healthy lifespan. Samsara's platform is the largest ever pipeline for the identification, chemical optimization, and in vivo validation of compounds that enhance autophagy. Samsara Therapeutics is a global biotech company with operations in Oxford and Boston and significant academic collaborations in Paris and Graz

Santhera Pharmaceuticals (SIX: SANN) is a Swiss specialty pharmaceutical company focused on the development and commercialization of innovative medicines for rare neuromuscular diseases with high unmet medical need. The Company has an exclusive license from ReveraGen for all indications worldwide to AGAMREE® (vamorolone), a dissociative steroid with novel mode of action, which was investigated in a pivotal study in patients with Duchenne muscular dystrophy (DMD) as an alternative to standard corticosteroids. AGAMREE for the treatment of DMD is approved in the U.S. by the Food and Drug Administration (FDA), in the EU by the European Medicines Agency (EMA), and in the UK by the Medicines and Healthcare products Regulatory Agency (MHRA). Santhera has out-licensed rights to AGAMREE for North America to Catalyst Pharmaceuticals, Inc. and for China to Sperogenix Therapeutics. For more information, please visit the Company's website at www.santhera.com

Scilligence is a leading innovator of cross-platform, mobile cheminformatics and bioinformatics software solutions. Its informatics tools have been widely adopted by pharmaceutical, biotech, and chemical industries, universities, research institutes, and government agencies. Scilligence's proprietary technologies address three main areas of R&D informatics needs: knowledge management and collaboration; project, workflow and material management; and knowledge mining of unstructured data. What makes the Scilligence platform different: -Powerful integration components for internal and external collaborations -A single platform supporting both small molecules and macromolecules -Truly designed for any device, browser, and platform -Absolutely no Java dependency -Fully supports HELM (Hierarchical Editing Language for Macromolecules) notation (Scilligence developed the JavaScript HELM Editor for Pistoia Alliance) -Developed completely by Scilligence allowing complete configuration and customization unique to each company, organization, or institution -Flexible workflow engine to enable process control and ease system integration -Cost effective in deployment and maintenance -Collaboration, workflow, and Project Management Platform -Connection to Equipment and Devices, Barcode Scan. Products: Scilligence ELN: Cross-Platform Electronic Lab Notebook for Chemistry and Biology RegMol: Cross-Platform Registration & Assay Database for Biologics, Small Molecules, and conjugates such as ADCs Scilligence Inventory: Cross-Platform Inventory System for Life Science R&D Scilligence PMF: Project, Workflow and Customer-Relationship Management System for Life Science R&D Scilligence SDMS: Cross-Platform Scientific Data Management System Scilligence CSM: Clinical Sample Management LIMS: Laboratory Information Management System Focus: Data Analytics and Ideation QMS: Quality Management System TouchMol4Office: Enables Cheminformatics and Bioinformatics in Microsoft Office

Scitara is a global provider of laboratory-specific, cloud-based software solutions for the life sciences and other science-based industries. Our solutions are powering the digital transformation of scientific laboratories by enabling them with modern lab data connectivity infrastructure and tools to accelerate science.​ Scitara DLX allows plug-and-play connectivity between any device, instrument, application, informatics system, web service or lab resource, using our connector technology, automation of workflows, task notifications, and bi-directional data exchange through our powerful and easy-to-use orchestration engine, compliant transformation of data in-flight using our transformation tools and libraries, and capture, monitoring, and analysis of all data transactions using our monitoring capabilities​. Scitara's lab informatics services are rooted in our deep laboratory domain experience, technology skills, and a global delivery model – allowing us to deliver services such as Scitara DLX platform deployment, validation, lab computing and cloud integration services to the highest standards of quality, capability and compliance. Scitara is Hiring! Please see our website for more information.

Scorpion is a clinical-stage, precision oncology company developing transformational targeted therapies for patients with cancer. We have built proprietary and fully-integrated discovery capabilities leveraging the most advanced technologies across cancer biology, medicinal chemistry and data sciences. Our current pipeline, led by our mutant-selective PI3Ka program STX-478, consists of three internally discovered clinical product candidates in addition to multiple discovery-stage programs. Our focus is on solving current gaps in therapeutic options for patients with cancer by discovering and developing exquisitely-selective product candidates against well-validated, previously undruggable targets to improve patient outcomes.

Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing the development of novel neuropsychiatric medicines in areas of high unmet patient needs. We have a proven strategy of advancing clinically validated mechanisms previously held back by limitations we overcome with our proprietary Glyph technology platform. All the therapeutic candidates in our pipeline of first and best-in-class medicines are based on the Glyph platform, which is uniquely designed to enable oral bioavailability, bypass first-pass metabolism and reduce hepatotoxicity and other side effects. We are led by an experienced team that was involved in inventing and developing KarXT and other neuropsychiatric medicines, and are guided by an extensive network of renowned scientists, clinicians and key opinion leaders.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs that are designed to restore health by repairing the function of a dysbiotic microbiome. The company's lead product candidate is the SER-109, which is in Phase III clinical development for preventing recurrence of clostridium difficile infection (CDI). It is also developing SER-287 that is in Phase IIb study treat ulcerative colitis; SER-401, a microbiome therapeutic candidate, which is in Phase Ib study for use with checkpoint inhibitors in patients with metastatic melanoma; and SER-301, an Ecobiotic microbiome therapeutic candidate for the treatment of inflammatory bowel disease. In addition, the company engages in the development of SER-262, to treat an initial recurrence of CDI; and SER-155 to modulate the microbiome and dysbiosis in patients following allogeneic hematopoietic stem cell transplants. The company has license and collaboration agreement with Nestec Ltd. and Memorial Sloan Kettering Cancer Center, as well as collaboration with AstraZeneca. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts

Servier is a privately held international pharmaceutical company headquartered in France with a passion for innovation that has improved patients' lives around the world. With $4.7 billion in annual sales Servier operates in almost 150 countries worldwide across five therapeutic categories including oncology, cardiovascular, immuno-inflammatory, neuroscience and diabetes. Servier is founded on the principle of serving and governed by an independent non-profit foundation. With this unique operating model, the company can be deliberate about putting patients ahead of profits. In fact, Servier re-invests 25 percent of revenue into research and development each year. Servier is committed to therapeutic progress to serve patient needs and strives to provide future generations with a world where quality healthcare is available and accessible to all. See our community guidelines here: https://www.servier.us/community-guidelines To report a suspected adverse event with a Servier product, please visit: https://www.servier.us/contact-us

Seyltx is a late clinical-stage pharmaceutical company leveraging new insights into how the brain functions to selectively target the "master switch" of the cough reflex to address refractory chronic cough - a condition that 4-5 million people in the US alone suffers from.

Sionna Therapeutics is a clinical stage company developing novel small molecule therapies targeting the most common genetic mutation affecting cystic fibrosis (CF) patients. The company is dedicated to developing highly effective and differentiated treatments for cystic fibrosis.

Solarea Bio is a clinical-stage biotechnology company in Cambridge, MA developing plant-based microbial solutions to some of the world's largest health problems. Solarea was founded in 2017 by a group of scientists and entrepreneurs eager to radically alter our understanding of the human microbiome and utilize its power to improve human health. The Solarea breakthrough came from the combined efforts of the company's co-founders who established a link between the discovery of an untapped source of microorganisms with probiotic potential in healthy foods, and their applications in inflammatory processes including the gut-musculoskeletal axis. Using powerful genomic and bioinformatic tools, Solarea is mining its novel microbial strain collection to identify synergistic combinations of microbes and prebiotic plant fibers to develop solutions for patients suffering from inflammatory processes.

Solid Biosciences (Solid) is a life science company singularly focused on solving Duchenne muscular dystrophy (Duchenne). We aim to be the center of excellence across the entire disease spectrum, serving as a catalyst to bring together those with the expertise in science, technology, disease management and care. Disease-focused and founded by a family directly impacted, our mandate is simple yet comprehensive - attack the roots of the disease and improve daily life for patients.

Solu Therapeutics is a precision-medicine company developing therapeutics to eliminate cells that drive oncologic, inflammatory, and autoimmune diseases.

Sonata Therapeutics is a new, Boston-based Flagship Pioneering company revolutionizing the world’s understanding of the cellular microenvironment and its importance to human biology and disease. Our product-platform creates drugs based on a systematic, comprehensive characterization of the microenvironment in diseases with high unmet medical need. Through our pioneering science, we identify new targets for therapeutics that induce the release of a programmed diversity of signals with the potential for significant patient impact. Our employees are exceptionally passionate, accountable, collaborative, and innovative. Sonata Therapeutics was founded by Flagship Pioneering, an organization dedicated to the origination and development of first-in-category life sciences companies.  Since 2000, Flagship has originated and fostered the development of nearly 100 scientific ventures resulting in $20+ billion in aggregate value, 500+ issued patents, and more than 50 clinical trials for novel therapeutic agents.  

We are a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for bacterial infections, including multi-drug resistant, or MDR, bacterial infections, and rare diseases. Spero’s lead product candidate, SPR720, is an oral antimicrobial agent in development for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease, a rare orphan disease. Spero’s partnership directed programs consist of SPR206 and tebipenem HBr, which through the company’s business development efforts, have joint venture relationships supporting their ongoing development. SPR206, is an IV-administered agent being developed as an innovative option to treat MDR Gram-negative bacterial infections, in the hospital setting. Tebipenem HBr, is designed to be the first broad-spectrum oral carbapenem-class antibiotic for use to treat certain bacterial infections that cause complicated urinary tract infections, or cUTIs, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited oral treatment options. We believe that our novel product candidates will have a meaningful impact on patient health and significant commercial applications for treating MDR infections in hospitals and community settings.

Our Mission Stealth BioTherapeutics is an innovative biopharmaceutical company developing therapies to treat mitochondrial dysfunction associated with genetic mitochondrial diseases and common diseases of aging. Our team works with patients and advocacy organizations to better understand their journey and raise awareness of the unmet need our programs seek to address. We collaborate with top-tier academic and medical institutions, scientific thought leaders, and clinical key opinion leaders in developing the first generation of targeted therapies focusing on mitochondrial dysfunction as it presents in these rare genetic diseases and common diseases of aging. With these collaborative efforts, we continue to advance our platform of late-stage clinical programs and novel pipeline candidates. Please be aware of the potential for scams claiming to represent Stealth BioTherapeutics in recruitment activities. Stealth exclusively uses @stealthbt.com e-mail addresses for recruitment purposes and does not conduct interviews via social media or other third-party sites. Please report any suspicious recruiting activity to us at careers@stealthbt.com and to the Internet Crime Complaint Center.

Sumitomo Pharma America (SMPA) is a science-based, technology-driven biopharmaceutical company focused on delivering therapeutic and scientific breakthroughs in areas of critical patient need in psychiatry and neurology, oncology, urology, women’s health, rare disease, and cell and gene therapies. SMPA was formed through the consolidation of Sumitomo Pharma’s U.S. affiliate companies including Sunovion Pharmaceuticals, Inc., Sumitomo Pharma America Holdings, Inc., Sumitomo Pharma Oncology, Inc., Sumitovant Biopharma, Inc., Myovant Sciences, Inc., Urovant Sciences, Inc. and Enzyvant Therapeutics, Inc. SMPA is a Sumitomo Pharma company.

Superluminal Medicines is a Boston-based generative biology and chemistry company developing a differentiated pipeline and revolutionizing the speed and accuracy of how medicine is created. Our platform creates candidate-ready compounds with unprecedented speed using a comprehensive combination of deep biology and chemistry expertise, machine learning, and proprietary big data infrastructure. The predict-design-test architecture accurately models protein shapes and designs highly selective compounds to target the precise structural change for therapeutic effect. Our discovery engine is powered by an industry-leading, pharmacokinetic and toxicology in silico prediction capability. With a lead program candidate expected in the near term, our proprietary pipeline validates our platform with initial programs focused on high-value GPCR targets. We’re pleased to be backed by a strong network of investors including RA Capital Management, Insight Partners, NVentures, Catalio Capital Management, Eli Lilly and Company, Gaingels, and Cooley LLP.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. Syndax corporate headquarters are in Waltham, MA.

SynDevRx is the first company developing treatments for cancer patients with baseline (or acquired) metabolic dysfunction with the only drug in clinical development that targets the underlying metabolic defect in cancer cells. The company's therapies focus on treating tumors sensitive to systemic, dysregulated metabolic hormones.

Synlogic is a clinical-stage biotechnology company advancing novel, oral, non-systemically absorbed biotherapeutics to transform the care of serious diseases in need of new treatment options. The Company’s late-stage pipeline is focused on rare metabolic diseases, led by labafenogene marselecobac (SYNB1934), currently being studied as a potential treatment for phenylketonuria (PKU) in Synpheny-3, a global, pivotal Phase 3 study. Additional product candidates address diseases including homocystinuria (HCU), enteric hyperoxaluria, gout, and cystinuria. This pipeline is fueled by the Synthetic Biotic platform, which applies precision genetic engineering to well-characterized probiotics. This enables Synlogic to create GI-restricted, oral medicines designed to consume or modify disease-specific metabolites – an approach well suited for PKU and HCU, both inborn errors of metabolism, as well as other disorders in which the disease–specific metabolites transit through the GI tract, providing validated targets for these Synthetic Biotics. Research activities include a partnership with Roche focused on inflammatory bowel disease (IBD), and a collaboration with Ginkgo Bioworks in synthetic biology, which has contributed to two pipeline programs to date. For more information, please visit www.synlogictx.com

Syntis Bio is a clinical-stage biopharmaceutical company developing oral therapies that harness the small intestine’s unique biology to provide accessible, effective and sustainable solutions across the healthcare spectrum, from rare genetic disorders to the world’s most prevalent conditions. Syntis is rapidly advancing a pipeline of oral therapies engineered for optimization in the small intestine, the body’s nexus for metabolic control, digestion and drug absorption. The company’s lead program, SYNT-101, is a once-daily oral pill for the treatment of obesity that mimics the effects of gastric bypass surgery. SYNT-101 leverages the power of SYNT™ (SYNthetic Tissue-lining), an oral technology developed by Syntis founders that delivers a safe, transient polymer coating to the duodenum that controls nutrient uptake, as well as enhances both gut-restricted enzyme efficacy and systemic drug absorption for up to 24 hours. Syntis is headquartered in Boston.

Syros is redefining the power of small molecules to control the expression of genes. Based on its unique ability to elucidate regulatory regions of the genome, Syros aims to develop medicines that provide a profound benefit for patients with diseases that have eluded other genomics-based approaches. Syros is advancing a robust pipeline, including SY-1425, a first-in-class oral selective RARα agonist in a Phase 2 trial in a genomically defined subset of acute myeloid leukemia patients, and SY-5609, a highly selective and potent oral CDK7 inhibitor in a Phase 1 trial in patients with select solid tumors. Syros also has multiple preclinical and discovery programs in oncology and monogenic diseases.

Tango Therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. Tango was launched in 2017 with a $55 million Series A investment from Third Rock Ventures. The company has established a robust product engine that leverages advances in DNA sequencing and CRISPR-based target discovery to generate breakthrough medicines that have the potential to provide deeper, more sustained benefit than today’s targeted therapies, and extend the benefit of available immuno-oncology agents. Tango Therapeutics is focused on three areas of drug development, each in well-defined patient populations currently lacking effective treatment options, and each with hallmarks of cancer that have not been targeted yet. These include: loss of tumor suppressor gene function; multiple oncogenic drivers; and immune evasion. What fuels each of Tango’s programs is an increasingly sophisticated ability to utilize synthetic lethality - the interaction between two genes that causes cell death when both are inactivated. In cancer cells, one of these genes is inactivated by mutation; the other will be inactivated by a drug. This approach leaves normal cells largely unaffected, with the potential to greatly enhance anti-tumor efficacy and reduce associated toxicity. Tango’s success will be driven by its depth of understanding of the genetic subtypes of cancer, and corresponding insights into novel drug targets and combinations uniquely relevant to each subtype. By shaping discovery efforts in this way, Tango has the potential to reach the clinic quickly, and with a clear plan for identifying the patients most likely to benefit from each new treatment, an approach that could increase both speed and probability of success in translating novel target discoveries into transformational new medicines for patients.

Employs an iterative biophysics and computational engine that addresses the challenges and limitations that have historically hampered efforts to drug RNA. Utilizes NMR (nuclear magnetic resonance spectroscopy)-derived ligand binding data to guide molecular dynamics simulations and build accurate structural models.

Targeting post-translational modification and metabolic synergy to expand and effectively target the druggable proteome

TauTaTis* takes a fundamentally new approach to prevent or halt Alzheimer's disease and a number of similar dementias.

Tectonic, co-founded by Andrew Kruse and Tim Springer of Harvard Medical School, is transforming the discovery of antibodies and other biologic drugs targeting G-protein Coupled Receptors (GPCRs). With our proprietary GEODe™ platform, we are targeting the most difficult, previously undruggable receptors in the class, aiming to unlock their therapeutic utility to develop new treatments for a broad range of patients with important unmet needs.

Tenza reprograms symbiotic bacteria from the human microbiome to administer medicines directly to the organs they naturally inhabit.

TetraGenetics harnesses the unique capabilities of the protozoa Tetrahymena thermophila to produce recombinant proteins for use in the discovery of novel antibody therapeutics targeting membrane proteins implicated in numerous human diseases.

Theracos is a pharmaceutical company that discovers, develops and commercializes medicines for important diseases.

Windshire Group, LLC (windshire.com) and Labshire, LLC (labshire.com) are leading global consulting firms that accelerates products to market by providing expert comprehensive CMC (Chemistry, Manufacturing, and Controls) technical, quality, laboratory, and management consulting, and services and solutions for all major therapeutic classes: biologics, monoclonal antibodies, cell and gene therapies, pharmaceuticals, vaccines, and biome. Our expert consultants are industry veterans with broad and global experience within product companies and CDMOs. Our team has worked with virtual companies to global conglomerates during all phases of the product life cycle and on all aspects of CMC and allied areas. We excel at surpassing client expectations, whether it be a solo, short-term consultation, or as an integrated, high performance team attacking challenges. Visit www.windshire.com and www.labshire.com.

Tobin Scientific is a provider of biopharma cold chain logistics, ambient storage, and laboratory relocation services. Founded in 1960 and headquartered in Beverly, Massachusetts, the company serves life sciences institutions, pharmaceutical companies, and research organizations. With a focus on compliance, redundancy, and sustainability, Tobin Scientific has established itself as a trusted partner for handling temperature-sensitive products. The company operates a 100,000-square-foot warehouse in the Boston metro area and has a national presence, offering coast-to-coast transport of live specimens and sensitive materials. Tobin Scientific's services include specialized transport under strict guidelines, GMP-compliant warehousing, and expert laboratory relocation. They also have licensed personnel trained in hazardous material logistics, ensuring the integrity of the chain of custody. Tobin Scientific emphasizes eco-conscious practices with energy-efficient equipment and multi-redundant systems for critical shipments. The company collaborates with biotech firms, academic institutions, and government agencies, and recently expanded its capabilities through the acquisition of BioRepository Resources.

Totus Medicines is applying revolutionary chemical biology technologies to create life-changing covalent therapeutics for untreatable diseases.

TransCode's lofty goal is delivering a cancer-free future for all cancer patients. Our core belief is that cancer can be overcome through the intelligent design and efficient delivery of targeted therapeutics. Our lead therapeutic candidate, TTX-MC138, targets microRNA-10b, or miRNA-10b, considered the master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and several others. Our other preclinical programs include two solid tumor programs, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L1, and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. TransCode also has three cancer agnostic programs, TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. Until now, targeting biomarkers that are the primary drivers of cancer onset, progression and recurrence have been locked behind the challenge of delivery – cytosolic delivery to engage these known targets. TransCode believes it has overcome this barrier, opening the door to a broad array of cancer therapies -- a disease with the highest unmet need that affects everyone. It is through the design and optimization of this technology that TransCode has devised an elegant solution -- TTX -- a proprietary delivery platform for the transport of targeted therapeutics to cancer cells. With their world class team and know how, TransCode has a rapidly expanding platform of drug candidates designed to target a variety of tumor indications with the goal of long-term treatment survival.

Treeline Biosciences is a biotech company building transformative precision medicines for patients with cancer and other serious conditions.

Tremeau is a Massachusetts-based pharmaceutical company focused on providing non-opioid pain treatments for well-defined patient populations with significant unmet needs. Tremeau’s unique approach to acute and chronic pain in select conditions is rooted in the mechanism of action, documented efficacy, and clinically differentiated profile of COX-2 selective NSAIDs.

TRIANA Biomedicines is a venture-backed biopharmaceutical company leading a transformative approach to discover and develop novel small molecules to treat disease. Our technology enables us to identify molecules that promote the interaction between a target and another protein in a way that alters the fate or function of the target protein. These innovative “molecular glues” allow us to treat disease in entirely new ways by pursuing highly disease relevant targets that have long been considered undruggable or are inadequately addressed.

Valerio Therapeutics is a clinical-stage biotechnology company based in France and the US that develops new drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). DDR consists of a network of cellular pathways that detect, report and repair DNA damage. Applied to oncology, this new field of research aims to weaken or block the ability of tumor cells to repair damage to their DNA, either naturally or under the effect of cytotoxic treatments. Focusing exclusively on intracellular DNA-binding targets, we design and develop first-in-class treatments for oncology and inflammatory diseases precision therapeutics from preclinical (translational) research to human clinical proof-of-concept studies. It thus leads its programs to the most value-creating and attractive inflection points for potential partners. The Company's portfolio is based on platON™, Valerio Therapeutic's decoy oligonucleotide platform. PlatON™ is intended to generate new compounds based on an unparalleled DDR decoy mechanism and capitalizing on the expertise the Company has developed on this type of oligonucleotides. The Company's portfolio includes: - AsiDNA™, a first-in-class product interfering with tumor DNA break repair, based on a decoy agonist mechanism, unmatched in the DDR field, which could, among other things, combat tumor resistance. AsiDNA™ is in clinical development in several trials, in combination with PARP inhibitors or in combination with radiation therapy. - A new family of compounds are positioned as a new-generation PARP agonists that are designed not to induce resistance and to activate the immune response. VIO-01, is currently being optimized in a preclinical phase. The Company is convinced of the significant therapeutic potential of its technology and the disruptive innovation it represents, which could pave the way for a new paradigm in cancer and inflammatory disease treatments.

Verastem Oncology (Nasdaq: VSTM) (Verastem, Inc.) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition and FAK inhibition. Pursuing unexplored pathways demands that we’re purposeful in everything we do. And it’s an endeavor that’s only possible with an experienced team of employees and partners dedicated to a singular purpose: changing and improving the way cancer is treated by delivering novel therapies that address areas of high unmet need in RAS/MAPK pathway-driven cancers. At Verastem Oncology, it takes our diversity of backgrounds, expertise, perspectives, and skills to find the answers that patients need, but don’t have—yet. To join our team or for more information, please visit www.verastem.com. X/Twitter: @VerastemOncolog

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. We discovered and developed the first medicines to treat the underlying cause of cystic fibrosis (CF), a rare, life-threatening genetic disease. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs focused on the underlying mechanisms of other serious diseases. Founded in 1989 in Cambridge, Massachusetts, our corporate headquarters is now located in Boston’s Innovation District, and our international headquarters is in London, United Kingdom. We currently employ approximately 3,500 people in the United States, Europe, Canada, Australia and Latin America with nearly two-thirds of our staff dedicated to research and development. Vertex is consistently recognized as one of the industry’s top places to work by Science Magazine, The Boston Globe, Boston Business Journal and the San Diego Business Journal. Our research and medicines have also received esteemed recognitions, including the Robert J. Beall Therapeutics Development Award, the French Prix Galien and the British Pharmacological Society awards.

Vigeo is focusing on tumors that are largely refractory to approved therapies. Our approach to drug development and treatment is based on targeting both the tumor and the genetically normal cells that comprise the microenvironment, which are less likely to develop mutation-based resistance. Therefore, we believe Vigeo’s therapies can have a significant impact on cancers where other types of therapy have been unsuccessful. Vigeo is the first, and only, company developing therapies designed to stimulate Tsp-1 expression by replicating the biological activity of prosaposin (PSAP). By triggering the production of TSP-1 and downstream activities via CD36 and CD47, we are reprogramming the tumor microenvironment from one that is immunosuppressive and tumor-promoting, to one that activates the immune system and is tumor-inhibiting.

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. We are utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in our efforts to develop precision-based therapies to improve the lives of patients and their families. VGL101, our lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. We are also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) in genetically defined subpopulations.

Viridian is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and protein engineering enables the development of differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas. Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The company is conducting two global Phase 3 clinical trials (THRIVE and THRIVE-2) to evaluate the safety and efficacy of VRDN-001 in patients with active and chronic TED. Viridian’s goal is to advance VRDN-001 as a potential best-in-class intravenous therapy followed by VRDN-003 as a potential first- and best-in-class subcutaneous therapy for the treatment of TED. In addition to its TED portfolio, Viridian is advancing a novel portfolio of neonatal Fc receptor (FcRn) inhibitors, including VRDN-006 and VRDN-008, which has the potential to be developed in multiple autoimmune diseases.

Virna Therapeutics is focused to develop neutralizing monoclonal antibody (mAb) that should prevent the SARS-CoV-2 from entering human host cells to combat the COVID-19, and also its other strains that could emerge as threats in the future. Virna Therapeutics has brought a multi-national team from USA, Canada, Italy and India to rapidly develop the therapeutic antibodies. The funding by Canadian Govt has been pivotal for discovery work thus far, and ministry of health has extended a full support for rapid development. Government of Italy has extended a full support for manufacturing and clinical development of the antibodies. Virna has identified an Indian Industry partner, Intonation Research Laboratories, Pvt. Ltd. Hyderabad, for an exclusive development and marketing right for South East Asia. The plan for India is to help in characterizing antibody, parallel scale up and clinical trials.

VRise Therapeutics is a global biotechnology company, which aspires to bring transformative change to the lives of cancer patients, through precision medicine.

Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. The company, with the help of its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

novel inhibitors of beta-catenin

X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, an oral small molecule antagonist of chemokine receptor CXCR4, which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; Phase Ib clinical trial to treat severe congenital neutropenia and Waldenström macroglobulinemia; and Phase IIa clinical trial for the treatment of clear cell renal cell carcinoma. The company is also developing X4P-002 for the treatment of glioblastoma multiforme; and X4P-003 to treat patients suffering from chronic rare diseases. X4 Pharmaceuticals, Inc. has a license agreement with Abbisko Therapeutics Co., Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

X-Chem is your preferred partner for innovative small molecule discovery. Synergizing DNA-encoded chemical library technology, discovery chemistry, and artificial intelligence, we provide pharmaceutical and biotech companies complete, seamless solutions for challenging, high-value therapeutic targets. With 80% success rate in identifying functional hits, ~100 programs licensed, 4 clinical candidates since 2021, and our technologies proven in ~30 challenging target classes, we are committed to helping create molecules that will improve human health. We work closely with our partners at any stage of early drug discovery, including screen-to-hit, hit-to-lead, lead optimization, and/or candidate identification to maximize project success. Our extensive expertise guarantees quality results, bringing our partners’ novel therapy closer to the clinic. Our clients benefit from flexible access to our innovations, including integrated project support, screening and follow-up, or access to our ArtemisAI software platform.

We are a quantum physics-based, AI-powered drug R&D company with the mission to revolutionize drug discovery and development by improving the speed, scale, novelty and success rate. With operations in both China and the U.S., we strive to deploy the best capabilities and resources available to us in each market to meet the needs of our customers and collaborators. Beyond our team’s domain expertise and creative thinking, the key to our mission is the integrated technology platform, which combines the mutually informing and reinforcing cloud supercomputing-powered in silico tools and our wet lab with robotic automation, and enables discovery and development of innovative therapeutics at a pace and scale beyond traditional alternatives. We are among the pioneering AI-powered drug R&D companies in the world that have established a platform with an iterative feedback loop between quantum physics-based dry lab and wet lab capabilities, according to Frost & Sullivan. With our platform designed to improve dry lab calculations with experimental data generated by the wet lab and enhance the efficiency of the wet lab by insights derived from dry lab calculations, we believe that we are well positioned at this moment where the combination of AI, computing power, data and automation is becoming increasingly critical for pharmaceutical development. Since our founding, we have received investments and support from world-renowned investors, and we believe this blue-chip shareholder base is a testament to our capabilities and prospects.

Yurogen Biosystems LLC is a private biotech company based in the Greater Boston area, a world-class biotech and biopharma hub. We are dedicated to produce premium antibodies and antibody-based products to meet broad needs of our clients. Along with our traditional polyclonal antibody production, Yurogen is commercializing an innovative platform that can efficiently develop monoclonal antibodies from a variety of host animals especially rabbit. Yurogen is developing a selection of antibodies that are widely used in in vitro diagnostics (IVD) as well as academic research. Our growing list of high quality antibodies are the reliable and cost-efficient tools that you can count on. Customized antibody services is offered at Yurogen to generate antibodies to meet the needs of our clients. Our state-of-the-art monoclonal antibody screening platform can significantly shorten the antibody screening process and yield high affinity monoclonal antibodies.

La Laiterie du Berger est une entreprise familiale sénégalaise, créée en 2006. Notre mission est de collecter le lait frais des éleveurs de notre pays, pour offrir chaque jour aux consommateurs sénégalais des produits laitiers, au lait local et naturel, connus sous la marque Dolima. C’est ce qui fait que la Laiterie du Berger n’est pas une entreprise comme les autres, et que le yaourt Dolima n’est pas un yaourt comme les autres. Notre engagement s’incarne dans notre mission sociale : construire une filière sénégalaise plus forte, avec un élevage plus productif, en mesure d’approvisionner le marché local. Il s’agit aussi de plus en plus d’aller vers la nutrition, pour apporter la santé par une alimentation saine et accessible dans notre pays où cet enjeu est si grand.